

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/CAPLUS enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007

=> file ca

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 5 Jul 2007 (20070705/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (drug-lipid complex?)
715681 DRUG
280382 LIPID
1668323 COMPLEX?
L1 18 (DRUG-LIPID COMPLEX?)
(DRUG(W)LIPID(W) COMPLEX?)

=> s (drug-lipid complex?)/ab,bi
362541 DRUG/AB
223463 LIPID/AB
1340517 COMPLEX?/AB
16 (DRUG-LIPID COMPLEX?)/AB
((DRUG(W)LIPID(W) COMPLEX?)/AB)
715681 DRUG/BI
280382 LIPID/BI
1668323 COMPLEX?/BI
18 (DRUG-LIPID COMPLEX?)/BI
((DRUG(W)LIPID(W) COMPLEX?)/BI)
L2 18 (DRUG-LIPID COMPLEX?)/AB,BI

=> d 1-18

L2 ANSWER 1 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 144:114413 CA
TI Preparation of a lipid complex for transmucosal drug delivery of gene or polypeptide drugs
IN Wei, Xiaohui; Xu, Yuhong
PA Shanghai Jiao Tong University, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 6 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1582900	A	20050223	CN 2004-10024892	20040603
PRAI	CN 2004-10024892		20040603		

L2 ANSWER 2 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:179607 CA
TI Wet-micro grinding for preparing a antitumor-lipid complex
IN Fu, Shu-Wen; Cheng, Chien-Hsin D.; Cheng, Jui-Ching; Hsiau, Yun-Yi
PA Peop. Rep. China
SO U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005169978	A1	20050804	US 2004-769118	20040129
PRAI	US 2004-769118		20040129		

L2 ANSWER 3 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 131:346112 CA

TI Preferential Distribution of Amphotericin B Lipid Complex into Human HDL3 Is a Consequence of High Density Lipoprotein Coat Lipid Content

AU Kennedy, Allison L.; Wasan, Kishor M.

CS Division of Pharmaceutics and Biopharmaceutics Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Can.

SO Journal of Pharmaceutical Sciences (1999), 88(11), 1149-1155

CODEN: JPMSAE; ISSN: 0022-3549

PB American Chemical Society

DT Journal

LA English

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 130:119111 CA

TI A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in hematological oncology

AU Clark, A. D.; McKendrick, S.; Tansey, P. J.; Franklin, I. M.; Chopra, R.

CS Glasgow Royal Infirmary, Glasgow, UK

SO British Journal of Haematology (1998), 103(1), 198-204

CODEN: BJHEAL; ISSN: 0007-1048

PB Blackwell Science Ltd.

DT Journal

LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 124:105434 CA

TI An acid hematein staining method suitable for detecting drug-induced lipidosis

AU Sugimoto, Tetsuro; Kajiwara, Maya; Chiba, Shuichi; Misawa, Yasuyuki; Niki, Rikio

CS Toxicology Research Laboratories, Chugai Pharmaceutical Co., Ltd., Nagano, 399-46, Japan

SO Journal of Toxicologic Pathology (1994), 7(3), 403-7

CODEN: JTPAE7; ISSN: 0914-9198

PB Japanese Society of Toxicologic Pathology

DT Journal

LA English

L2 ANSWER 6 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 118:225001 CA

TI Direct connection between myelinosomes, endoplasmic reticulum and nuclear envelope in mouse hepatocytes grown with the amphiphilic drug, quinacrine

AU Prince, J. S.; Kohen, C.; Kohen, E.; Jimenez, J.; Brada, Z.

CS Biol. Dep., Univ. Miami, Coral Gables, FL, 33124, USA

SO Tissue & Cell (1993), 25(1), 103-10

CODEN: TICEBI; ISSN: 0040-8166

DT Journal

LA English

L2 ANSWER 7 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 118:139187 CA

TI Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins

AU Wasan, Kishor M.; Brazeau, Gayle A.; Keyhani, Afsane; Hayman, Alan C.; Lopez-Berestein, Gabriel

CS Dep. Pharm., Univ. Houston, Houston, TX, 77030, USA

SO Antimicrobial Agents and Chemotherapy (1993), 37(2), 246-50

CODEN: AMACCQ; ISSN: 0066-4804

DT Journal

LA English

L2 ANSWER 8 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 118:32538 CA
TI Accessibility of aminoglycosides, isolated and in interaction with phosphatidylinositol, to water. A conformational analysis using the concept of molecular hydrophobicity potential
AU Mingeot-Leclercq, M. P.; Tulkens, P. M.; Brasseur, R.
CS Lab. Chim. Physiol., Univ. Cathol. Louvain, Brussels, Belg.
SO Biochemical Pharmacology (1992), 44(10), 1967-75
CODEN: BCPA6; ISSN: 0006-2952
DT Journal
LA English

L2 ANSWER 9 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 117:157510 CA
TI Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity
AU Perkins, Walter R.; Minchey, Sharma R.; Boni, Lawrence T.; Swenson, Christine E.; Popescu, Mircea C.; Pasternack, Robert F.; Janoff, Andrew S.
CS Liposome Co. Inc., Princeton, NJ, 08540, USA
SO Biochimica et Biophysica Acta, Biomembranes (1992), 1107(2), 271-82
CODEN: BBBMBS; ISSN: 0005-2736
DT Journal
LA English

L2 ANSWER 10 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 115:189688 CA
TI Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate disks
AU Guo, Luke S. S.; Fielding, Robert M.; Lasic, Danilo D.; Hamilton, Robert L.; Mufson, Daniel
CS Liposome Technol. Inc., Menlo Park, CA, 94025, USA
SO International Journal of Pharmaceutics (1991), 75(1), 45-54
CODEN: IJPHDE; ISSN: 0378-5173
DT Journal
LA English

L2 ANSWER 11 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 115:35583 CA
TI Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen
AU Boggs, J. M.; Chang, N. H.; Goundalkar, A.
CS Res. Inst., Hosp. Sick Child., Toronto, ON, M5G 1X8, Can.
SO Antimicrobial Agents and Chemotherapy (1991), 35(5), 879-85
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English

L2 ANSWER 12 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 112:229346 CA
TI Interaction of antimycobacterial and antipneumocystis drugs with phospholipid membranes
AU Pedroso de Lima, Maria C.; Chiche, Bich H.; Debs, Robert J.; Duzgunes, Nejat
CS Cancer Res. Inst., Univ. California, San Francisco, CA, 94143-0128, USA
SO Chemistry and Physics of Lipids (1990), 53(4), 361-71
CODEN: CPLIA4; ISSN: 0009-3084
DT Journal
LA English

L2 ANSWER 13 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 111:219283 CA
TI Method for size separation of particles such as drug-containing liposomes
IN Lenk, Robert P.; Durning, Anthony G.; Klimchak, Robert J.; Portnoff, Joel; Tomsho, Michelle L.
PA Liposome Co., Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8900846	A1	19890209	WO 1988-US2598	19880728
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 394265	A1	19901031	EP 1988-906769	19880728
	EP 394265	B1	19941102		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02504362	T	19901213	JP 1988-506866	19880728
	JP 2877160	B2	19990331		
	CA 1337273	C	19951010	CA 1988-573460	19880729
	US 5948441	A	19990907	US 1995-367923	19950103
	US 5616334	A	19970401	US 1995-430699	19950428
	US 6406713	B1	20020618	US 1995-430661	19950428
	US 2002119170	A1	20020829	US 2002-132151	20020426
PRAI	US 1987-79309	A	19870729		
	US 1988-164580	A	19880307		
	US 1987-22157	B2	19870305		
	US 1987-69908	B2	19870706		
	US 1987-136267	A2	19871222		
	US 1988-225327	A	19880728		
	WO 1988-US2598	W	19880728		
	US 1988-236700	B1	19880825		
	US 1992-876121	B1	19920429		
	US 1993-52815	B1	19930423		
	US 1995-430661	A1	19950428		

L2 ANSWER 14 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 110:219106 CA

TI **Drug-lipid complexes** and a method for their preparation in aqueous solvents

IN Janoff, Andrew S.; Boni, Lawrence; Madden, Thomas; Cullis, Pieter R.; Lenk, Robert P.; Kearns, John J.; Durning, Anthony G.

PA Liposome Co., Inc., USA

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8806443	A1	19880907	WO 1988-US647	19880303
	W: AU, DK, FI, HU, JP, KR, NO				
	CA 1338701	C	19961112	CA 1988-560121	19880229
	ZA 8801477	A	19881026	ZA 1988-1477	19880302
	IL 85607	A	19920818	IL 1988-85607	19880302
	AU 8817990	A	19880926	AU 1988-17990	19880303
	AU 622405	B2	19920409		
	JP 02502460	T	19900809	JP 1988-504538	19880303
	JP 2705175	B2	19980126		
	HU 53280	A2	19901028	HU 1988-3963	19880303
	HU 209647	B	19940928		
	EP 282405	A2	19880914	EP 1988-400520	19880304
	EP 282405	A3	19890104		
	EP 282405	B1	19950208		
	EP 282405	B2	19980722		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ES 2070131	T3	19950601	ES 1988-400520	19880304
	CN 88101864	A	19880928	CN 1988-101864	19880305
	CN 1044093	B	19990714		
	CA 1337273	C	19951010	CA 1988-573460	19880729
	NO 8804391	A	19881124	NO 1988-4391	19881004
	NO 179995	B	19961021		
	NO 179995	C	19970129		
	KR 9702870	B1	19970312	KR 1988-71402	19881104
	DK 8900980	A	19890301	DK 1989-980	19890301
	DK 176010	B1	20051128		
	DK 8900982	A	19890904	DK 1989-982	19890301

FI 102724	B	19990215	FI 1989-4161	19890904
FI 102724	B1	19990215		
NO 180147	B	19961118	NO 1994-4071	19941026
NO 180147	C	19970226		
US 5616334	A	19970401	US 1995-430699	19950428
US 6406713	B1	20020618	US 1995-430661	19950428
US 2002119170	A1	20020829	US 2002-132151	20020426
PRAI US 1987-22157	A	19870305		
US 1987-69908	A	19870706		
US 1987-79309	A	19870729		
US 1987-136267	A2	19871222		
WO 1988-US647	A	19880303		
US 1988-164580	B2	19880307		
US 1988-225327	A	19880728		
US 1988-236700	B1	19880825		
NO 1988-4391	A	19881004		
US 1992-876121	B1	19920429		
US 1995-430661	A1	19950428		

L2 ANSWER 15 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 108:226691 CA
 TI Scale-up of liposome products
 AU Klimchak, Robert J.; Lenk, Robert P.
 CS Liposome Co., Inc., Princeton, NJ, 08540, USA
 SO BioPharm Manufacturing (1988), 1(2), 18-21
 CODEN: BIMA EV; ISSN: 1040-8045
 DT Journal; General Review
 LA English

L2 ANSWER 16 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 90:179929 CA
 TI Phospholipase inactivation induced by an amino-piperazine derivative: a study at the lipid-water interface
 AU Defrise-Quertain, F.; Chatelain, P.; Ruysschaert, J. M.
 CS Lab. Chim. Phys. Macromol., Univ. Libre Bruxelles, Brussels, Belg.
 SO Journal of Pharmacy and Pharmacology (1978), 30(10), 608-12
 CODEN: JPPMAB; ISSN: 0022-3573
 DT Journal
 LA English

L2 ANSWER 17 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 68:112837 CA
 TI Retention or efflux of phthalanilide (NSC 60339). Lipid complexes by sensitive or resistant murine tumor cells and Escherichia coli B
 AU Yesair, David W.; HoFook, Carmen
 CS Life Sci. Div., Arthur D. Little, Inc., Cambridge, MA, USA
 SO Cancer Research (1968), 28(2), 314-19
 CODEN: CNREA8; ISSN: 0008-5472
 DT Journal
 LA English

L2 ANSWER 18 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 62:77248 CA
 OREF 62:13708f-h
 TI Search for metabolites of antileukemic phthalanilides, 2-chloro-4',4''-bis(2-imidazolin-2-yl)terephthalanilide (NSC-60339) and 2-amino-4',4''-bis(2-imadazolin-2-yl)terephthalanilide dihydrochloride (NSC-50469)
 AU Booth, J.; Boyland, E.; Gellhorn, A.
 CS Roy. Cancer Hosp., London
 SO Cancer Chemotherapy Rept. (1964), No. 43, 11-8
 DT Journal
 LA English

=> file uspatall
 COST IN U.S. DOLLARS

SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST

38.97

39.18

FILE 'USPATFULL' ENTERED AT 20:54:00 ON 11 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (drug-lipid complex?)
L3 42 (DRUG-LIPID COMPLEX?)

=> s (drug-lipid complex?)/clm
L4 3 (DRUG-LIPID COMPLEX?)/CLM

=> s (mechanic means or dispersion mill or attritor mill or vibrator mill or media mill or ba
L5 37993 (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRATOR
MILL OR MEDIA MILL OR BALL MILL)

=> s (mechanic means or dispersion mill or attritor mill or vibrator mill or media mill or ba
L6 1035 (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRATOR
MILL OR MEDIA MILL OR BALL MILL)/CLM

=> s l3 and l5
L7 2 L3 AND L5

=> d 1-2

L7 ANSWER 1 OF 2 USPATFULL on STN

Full Text

AN 2005:195837 USPATFULL
TI Wet-micro grinding
IN Fu, Shu-Wen, Hsin Chu City, CHINA
Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI US 2005169978 A1 20050804
AI US 2004-769118 A1 20040129 (10)
DT Utility
FS APPLICATION
LN.CNT 435
INCL INCLM: 424/450.000
INCLS: 514/034.000; 514/283.000; 514/449.000
NCL NCLM: 424/450.000
NCLS: 514/034.000; 514/283.000; 514/449.000
IC [7]
ICM A61K009-127
ICS A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 2 USPATFULL on STN

Full Text

AN 95:13613 USPATFULL
TI Solid care therapeutic compositions and methods for making same
IN Chagnon, Mark S., Pelham, NH, United States
Ferris, John R., Newburyport, MA, United States
Hamilton, Tracy J., Salem, NH, United States
Rudd, Edwin A., Salem, NH, United States
Carter, Michelle J., Derry, NH, United States
PA Molecular Bioquest, Inc., Atkinson, NH, United States (U.S. corporation)
PI US 5389377 19950214
AI US 1992-958646 19921007 (7)
RLI Continuation-in-part of Ser. No. US 1992-894260, filed on 8 Jun 1992
which is a continuation-in-part of Ser. No. US 1990-566169, filed on 10
Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US
1989-455071, filed on 22 Dec 1989, now abandoned
DT Utility
FS Granted
LN.CNT 678
INCL INCLM: 424/450.000
INCLS: 424/490.000; 424/498.000; 424/600.000; 424/617.000; 424/630.000;
424/635.000; 424/639.000; 424/641.000; 424/644.000; 424/646.000;
424/650.000; 428/402.240

NCL NCLM: 424/450.000
NCLS: 424/490.000; 424/498.000; 424/600.000; 424/617.000; 424/630.000;
424/635.000; 424/639.000; 424/641.000; 424/644.000; 424/646.000;
424/650.000; 428/402.240

IC [6]

ICM A61K009-127

EXF 424/450; 424/417; 424/420; 424/600; 424/641; 424/617; 428/402.2;
428/402.24; 428/490; 428/498; 428/630; 428/635; 428/639; 428/644;
428/646; 428/650

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007

L1 18 S (DRUG-LIPID COMPLEX?)

L2 18 S (DRUG-LIPID COMPLEX?)/AB,BI

FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007

L3 42 S (DRUG-LIPID COMPLEX?)

L4 3 S (DRUG-LIPID COMPLEX?)/CLM

L5 37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT

L6 1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT

L7 2 S L3 AND L5

=> s 14 and 16

L8 1 L4 AND L6

=> d

L8 ANSWER 1 OF 1 USPATFULL on STN

Full Text

AN 2005:195837 USPATFULL

TI Wet-micro grinding

IN Fu, Shu-Wen, Hsin Chu City, CHINA

Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES

Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA

Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA

PI US 2005169978 A1 20050804

AI US 2004-769118 A1 20040129 (10)

DT Utility

FS APPLICATION

LN.CNT 435

INCL INCLM: 424/450.000

INCLS: 514/034.000; 514/283.000; 514/449.000

NCL NCLM: 424/450.000

NCLS: 514/034.000; 514/283.000; 514/449.000

IC [7]

ICM A61K009-127

ICS A61K009-16; A61K009-50

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007

L1 18 S (DRUG-LIPID COMPLEX?)

L2 18 S (DRUG-LIPID COMPLEX?)/AB,BI

FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007

L3 42 S (DRUG-LIPID COMPLEX?)

L4 3 S (DRUG-LIPID COMPLEX?)/CLM

L5 37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT

L6 1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT

L7 2 S L3 AND L5

L8 1 S L4 AND L6

=> d 17 an ti in pi kwic 2

L7 ANSWER 2 OF 2 USPATFULL on STN

Full Text

AN 95:13613 USPATFULL
TI Solid care therapeutic compositions and methods for making same
IN Chagnon, Mark S., Pelham, NH, United States
Ferris, John R., Newburyport, MA, United States
Hamilton, Tracy J., Salem, NH, United States
Rudd, Edwin A., Salem, NH, United States
Carter, Michelle J., Derry, NH, United States
PI US 5389377 19950214
SUMM . . . used to treat cancer and infectious diseases. The use of liposomes and other lipid structures, such as micro-emulsions, micelles, and drug/lipid complexes, for drug delivery has been widely proposed. Such lipid structures, and particularly liposomes, have the potential for providing controlled release.
DETD . . . collect the crystal between washes. The crystals are then milled to a more controlled particle size, for example, in a ball mill, under conditions sufficient to form 50 Angstroms or lower particle size. See, commonly assigned U.S. Pat. No. 5,071,076, and copending.
DETD . . . Fe₃O₄:acid equal to 2:1 weight percent. After mechanically milling the mixture for 1 to 1.5 hours on a ball mill with 4 mm glass media, the acid coated particles collapse around the media allowing for easy removal of water without.

=> s phospholipid?

L9 20 PHOSPHILIPID?

=> s phospholipid?

L10 20 PHOSPHILIPID?

=> s phospholipid?

L11 50032 PHOSPHOLIPID?

=> s phospholipid?/clm

L12 5315 PHOSPHOLIPID?/CLM

=> s 15 and 111

L13 478 L5 AND L11

=> s 16 and 112

L14 9 L6 AND L12

=> d 1-9

L14 ANSWER 1 OF 9 USPATFULL on STN

Full Text

AN 2006:33785 USPATFULL
TI Carrier particles for use in dry powder inhalers
IN Staniforth, John Nicholas, Bath, UNITED KINGDOM
PA Vectura Limited, Chippenham, UNITED KINGDOM (non-U.S. corporation)
PI US 2006029552 A1 20060209
AI US 2005-202741 A1 20050811 (11)
RLI Continuation of Ser. No. US 2002-306865, filed on 27 Nov 2002, PENDING
Continuation of Ser. No. US 2000-680863, filed on 6 Oct 2000, GRANTED,
Pat. No. US 6521260 Continuation of Ser. No. US 1997-875391, filed on 25
Sep 1997, GRANTED, Pat. No. US 6153224 A 371 of International Ser. No.
WO 1996-GB2115, filed on 31 Jan 1996
PRAI GB 1995-1841 19950131
GB 1995-21937 19951026
DT Utility
FS APPLICATION
LN.CNT 1456
INCL INCLM: 424/046.000
INCLS: 514/053.000
NCL NCLM: 424/046.000
NCLS: 514/053.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 2 OF 9 USPATFULL on STN

Full Text

AN 2005:195837 USPATFULL
TI Wet-micro grinding
IN Fu, Shu-Wen, Hsin Chu City, CHINA
Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI US 2005169978 A1 20050804
AI US 2004-769118 A1 20040129 (10)
DT Utility
FS APPLICATION
LN.CNT 435
INCL INCLM: 424/450.000
INCLS: 514/034.000; 514/283.000; 514/449.000
NCL NCLM: 424/450.000
NCLS: 514/034.000; 514/283.000; 514/449.000
IC [7]
ICM A61K009-127
ICS A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 9 USPATFULL on STN

Full Text

AN 2004:15020 USPATFULL
TI Method for producing powdery particle-reduced formulations with the aid
of compressed gases
IN Heidlas, Jurgen, Trostberg, GERMANY, FEDERAL REPUBLIC OF
Ober, Martin, Altenmarkt, GERMANY, FEDERAL REPUBLIC OF
Wiesmuller, Johann, Garching, GERMANY, FEDERAL REPUBLIC OF
PA Degussa AG, Trostberg, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
corporation)
PI US 6680284 B1 20040120
WO 2001003671 20010118
AI US 2002-30035 20020103 (10)
WO 2000-EP6709 20000713
PRAI DE 1999-19932648 19990713
DE 1999-19960167 19991214
DT Utility
FS GRANTED
LN.CNT 451
INCL INCLM: 504/367.000
INCLS: 424/489.000; 424/499.000; 424/500.000; 424/501.000; 424/502.000;
514/959.000; 516/001.000; 516/114.000; 516/922.000; 516/928.000
NCL NCLM: 504/367.000
NCLS: 424/489.000; 424/499.000; 424/500.000; 424/501.000; 424/502.000;
514/959.000; 516/001.000; 516/114.000; 516/922.000; 516/928.000
IC [7]
ICM A01N025-12
ICS A61K009-16; B01J003-00
EXF 424/489; 424/499; 424/500; 424/501; 424/502; 514/951; 504/367; 516/1;
516/114; 516/922; 516/928
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 9 USPATFULL on STN

Full Text

AN 2003:243774 USPATFULL
TI Carrier particles for use in dry powder inhalers
IN Staniforth, John Nicholas, Bath, UNITED KINGDOM
PA Vectura Limited, London, UNITED KINGDOM (non-U.S. corporation)
PI US 2003170183 A1 20030911
US 7011818 B2 20060314
AI US 2002-306865 A1 20021127 (10)
RLI Continuation of Ser. No. US 2000-680863, filed on 6 Oct 2000, GRANTED,
Pat. No. US 6521260 Continuation of Ser. No. US 1997-875391, filed on 25
Sep 1997, GRANTED, Pat. No. US 6153224 A 371 of International Ser. No.
WO 1996-GB215, filed on 31 Jan 1996, UNKNOWN
PRAI GB 1995-1841 19950131
GB 1995-21937 19951026
DT Utility
FS APPLICATION
LN.CNT 1513
INCL INCLM: 424/046.000

NCL NCLM: 424/045.000; 424/046.000
 NCLS: 424/046.000; 424/452.000; 424/489.000; 424/490.000; 514/561.000
 IC [7]
 ICM A61L009-04
 ICS A61K009-14
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 9 USPATFULL on STN

Full Text

AN 2002:90568 USPATFULL
 TI Milled particles
 IN Verhoff, Frank, Cincinnati, OH, UNITED STATES
 Pace, Gary W., Winchester, MA, UNITED STATES
 Snow, Robert A., West Chester, PA, UNITED STATES
 Millar, Fay, Ladson, SC, UNITED STATES
 PI US 2002047058 A1 20020425
 US 6634576 B2 20031021
 AI US 2001-940864 A1 20010829 (9)
 PRAI US 2000-229042P 20000831 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4197
 INCL INCLM: 241/026.000
 INCLS: 424/489.000
 NCL NCLM: 241/021.000; 241/026.000
 NCLS: 241/184.000; 424/489.000
 IC [7]
 ICM B02C017-00
 ICS A61K009-14
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 9 USPATFULL on STN

Full Text

AN 2002:7196 USPATFULL
 TI Media milling
 IN Verhoff, Frank H., Cincinnati, OH, UNITED STATES
 Snow, Robert A., West Chester, PA, UNITED STATES
 Pace, Gary W., Winchester, MA, UNITED STATES
 PI US 2002003179 A1 20020110
 US 6604698 B2 20030812
 AI US 2001-852054 A1 20010510 (9)
 PRAI US 2000-203366P 20000510 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2454
 INCL INCLM: 241/021.000
 INCLS: 241/172.000
 NCL NCLM: 241/021.000
 NCLS: 241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
 IC [7]
 ICM B02C017-16

L14 ANSWER 7 OF 9 USPATFULL on STN

Full Text

AN 1999:4081 USPATFULL
 TI Pharmaceutical nanosuspensions for medicament administration as systems
 with increased saturation solubility and rate of solution
 IN Muller, Rainer H., Berlin, Germany, Federal Republic of
 Becker, Robert, Biberach, Germany, Federal Republic of
 Kruss, Bernd, Hochdorf, Germany, Federal Republic of
 Peters, Katrin, Berlin, Germany, Federal Republic of
 PA Medac Gesellschaft Fur Klinische Spezialpraparate, Hamburg, Germany,
 Federal Republic of (non-U.S. corporation)
 PI US 5858410 19990112
 WO 9614830 19960523
 AI US 1997-836305 19970619 (8)
 WO 1995-EP4401 19951109
 19970619 PCT 371 date
 19970619 PCT 102(e) date
 PRAI DE 1994-4440337 19941111
 DT Utility
 FS Granted

LN.CNT 1289
INCL INCLM: 424/489.000
INCLS: 424/491.000; 424/493.000; 424/494.000; 424/495.000; 424/499.000
NCL NCLM: 424/489.000
NCLS: 424/491.000; 424/493.000; 424/494.000; 424/495.000; 424/499.000
IC [6]
ICM A61K009-14
EXF 424/489; 424/491; 424/493; 424/494; 424/495; 424/499
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 8 OF 9 USPAT2 on STN

Full Text

AN 2002:90568 USPAT2
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, United States
Pace, Gary W., Winchester, MA, United States
Snow, Robert A., West Chester, PA, United States
Millar, Fay, Ladson, SC, United States
PA RTP Pharma Inc., Durham, NC, United States (U.S. corporation)
PI US 6634576 B2 20031021
AI US 2001-940864 20010829 (9)
PRAI US 2000-229042P 20000831 (60)
DT Utility
FS GRANTED
LN.CNT 4045
INCL INCLM: 241/021.000
INCLS: 241/184.000
NCL NCLM: 241/021.000; 241/026.000
NCLS: 241/184.000; 424/489.000
IC [7]
ICM B02C012-14
EXF 241/21; 241/184; 241/171; 241/172; 241/23; 241/24.12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 9 OF 9 USPAT2 on STN

Full Text

AN 2002:7196 USPAT2
TI Media milling
IN Verhoff, Frank H., Cincinnati, OH, United States
Snow, Robert A., West Chester, PA, United States
Pace, Gary W., Raleigh, NC, United States
PA SkyePharma Canada, Inc., Montreal, CANADA (non-U.S. corporation)
PI US 6604698 B2 20030812
AI US 2001-852054 20010510 (9)
PRAI US 2000-203366P 20000510 (60)
DT Utility
FS GRANTED
LN.CNT 2454
INCL INCLM: 241/021.000
INCLS: 214/184.000
NCL NCLM: 241/021.000
NCLS: 241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
IC [7]
ICM B02C017-16
ICS B02C019-12
EXF 214/184; 214/172; 214/171; 214/30; 214/21; 214/18; 214/57; 214/62;
424/450

=> d an ti in pa pi kwic 1-9

L14 ANSWER 1 OF 9 USPATFULL on STN

Full Text

AN 2006:33785 USPATFULL
TI Carrier particles for use in dry powder inhalers
IN Staniforth, John Nicholas, Bath, UNITED KINGDOM
PA Vectura Limited, Chippenham, UNITED KINGDOM (non-U.S. corporation)
PI US 2006029552 A1 20060209
CLM What is claimed is:
61. A method as claimed in claim 60, wherein the milling step is performed in a ball mill.

78. A method as claimed in claim 50, wherein the additive material comprises a **phospholipid** or a derivative thereof.

L14 ANSWER 2 OF 9 USPATFULL on STN

Full Text

AN 2005:195837 USPATFULL

TI Wet-micro grinding

IN Fu, Shu-Wen, Hsin Chu City, CHINA

Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES

Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA

Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA

PI US 2005169978 A1 20050804

CLM What is claimed is:

1. A method for preparing a drug-lipid complex, comprising dispersing a drug and one or more **phospholipids** in an aqueous solution to obtain a mixture, in which the molar ratio between the drug and the lipids ranges from 1:9 to 9:1; and grinding the mixture with a **mechanic means** to obtain a drug-lipid complex that does not have a captured volume.

2. The method of claim 1, wherein the **phospholipids** are dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol.

16. The method of claim 1, wherein the **mechanic means** is a **dispersion mill**.

17. The method of claim 16, wherein the **dispersion mill** is a **ball mill**.

18. The method of claim 17, wherein the **phospholipids** are dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol.

32. A method for preparing a drug-containing liposome, comprising dispersing a drug and one or more **phospholipids** in an aqueous solution to obtain a mixture, in which the molar ratio between the drug and the lipids ranges from 1:99 to 1:9; and grinding the mixture with a **mechanic means** to obtain a drug-containing liposome.

33. The method of claim 32, wherein the **phospholipids** are egg phosphatidylcholine and egg phosphatidylglycerol.

44. The method of claim 32, wherein the **mechanic means** is a **dispersion mill**.

45. The method of claim 44, wherein the **dispersion mill** is a **ball mill**.

46. The method of claim 45, wherein the **phospholipids** are egg phosphatidylcholine and egg phosphatidylglycerol.

L14 ANSWER 3 OF 9 USPATFULL on STN

Full Text

AN 2004:15020 USPATFULL

TI Method for producing powdery particle-reduced formulations with the aid of compressed gases

IN Heidlas, Jurgen, Trostberg, GERMANY, FEDERAL REPUBLIC OF

Ober, Martin, Altenmarkt, GERMANY, FEDERAL REPUBLIC OF

PA Wiesmuller, Johann, Garching, GERMANY, FEDERAL REPUBLIC OF

Degussa AG, Trostberg, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PI US 6680284 B1 20040120

WO 2001003671 20010118

CLM What is claimed is:

. The process as claimed in claim 1, wherein the grinding step is conducted in a stirred autoclave having an integrated **ball mill**.

21. The process of claim 20, wherein said carrier material is selected from the group consisting of a **phospholipid**, a partial glyceride, a carbohydrate derivative, a polymers, a polyethylene glycol, a silicone derivative, and a gelatin.

L14 ANSWER 4 OF 9 USPATFULL on STN

Full Text

AN 2003:243774 USPATFULL
TI Carrier particles for use in dry powder inhalers
IN Staniforth, John Nicholas, Bath, UNITED KINGDOM
PA Vectura Limited, London, UNITED KINGDOM (non-U.S. corporation)
PI US 2003170183 A1 20030911
US 7011818 B2 20060314
CLM What is claimed is:
12. A powder according to claim 11, wherein the additive material comprises a **phospholipid** or a derivative thereof.
42. A method according to claim 41 wherein the milling step is performed in a **ball mill**.

L14 ANSWER 5 OF 9 USPATFULL on STN

Full Text

AN 2002:90568 USPATFULL
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, UNITED STATES
Pace, Gary W., Winchester, MA, UNITED STATES
Snow, Robert A., West Chester, PA, UNITED STATES
Millar, Fay, Ladson, SC, UNITED STATES
PI US 2002047058 A1 20020425
US 6634576 B2 20031021
CLM What is claimed is:
1. A process for preparing a synergetic commixture comprising small particles of a solid substrate and small particulates of a . . . first material of a desired size, said process comprising the steps of: a) providing to the milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of first material to produce. . .
11. The process of claim 2 or 3, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.
12. The process of claim 2 or 3, wherein the surface active substance is a **phospholipid**.
13. The process of claim 12, wherein the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine, . . .
27. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid.
1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at the exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L14 ANSWER 6 OF 9 USPATFULL on STN

Full Text

AN 2002:7196 USPATFULL
TI Media milling
IN Verhoff, Frank H., Cincinnati, OH, UNITED STATES
Snow, Robert A., West Chester, PA, UNITED STATES
Pace, Gary W., Winchester, MA, UNITED STATES
PI US 2002003179 A1 20020110
US 6604698 B2 20030812
CLM What is claimed is:
carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said.
5. The process of claim 1 where the surface active substance is selected from the group consisting of a **phospholipid**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and

colloidal clays.

6. The process of claim 5 where the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine, . . .

L14 ANSWER 7 OF 9 USPATFULL on STN

Full Text

AN 1999:4081 USPATFULL

TI Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution

IN Muller, Rainer H., Berlin, Germany, Federal Republic of

Becker, Robert, Biberach, Germany, Federal Republic of

Kruss, Bernd, Hochdorf, Germany, Federal Republic of

Peters, Katrin, Berlin, Germany, Federal Republic of

PA Medac Gesellschaft Fur Klinische Spezialpraparate, Hamburg, Germany, Federal Republic of (non-U.S. corporation)

PI US 5858410 19990112

WO 9614830 19960523

CLM What is claimed is:

. . . solubility and an increased rate of dissolution compared with powders of the active compound prepared using an ultrasonic probe, a **ball mill** or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using a piston-gap. . .

. . . esters, polyglycerol ethers and esters, lecithins, esters and ethers of sugars or sugar alcohols with fatty acids or fatty alcohols, **phospholipids** and sphingolipids, sterols, esters or ethers thereof and mixtures of these compounds.

. . . egg lecithin, soya lecithin or hydrogenated lecithin, mixtures thereof or mixtures of one or both lecithins with one or more **phospholipid** components, cholesterol, cholesterol palmitate, or stigmasterol.

. . . solubility and an increased rate of dissolution compared with powders of the active compound prepared using an ultrasonic probe, a **ball mill** or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using cavitation or. . .

L14 ANSWER 8 OF 9 USPAT2 on STN

Full Text

AN 2002:90568 USPAT2

TI Milled particles

IN Verhoff, Frank, Cincinnati, OH, United States

Pace, Gary W., Winchester, MA, United States

Snow, Robert A., West Chester, PA, United States

Millar, Fay, Ladson, SC, United States

PA RTP Pharma Inc., Durham, NC, United States (U.S. corporation)

PI US 6634576 B2 20031021

CLM What is claimed is:

. . . particulates of a first material of a desired size, said process comprising: a) providing to a milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of the first material to. . .

. . . of claim 3, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

5. The process of claim 3, wherein the one or more than one surface active substance is a **phospholipid**.

6. The process of claim 5, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . .

. . . of claim 2, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic

surfactants, and colloidal clays.

15. The process of claim 2, wherein the one or more than one surface active substance is a **phospholipid**.

16. The process of claim 15, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean.

30. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid substrate.

1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at an exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L14 ANSWER 9 OF 9 USPAT2 on STN

Full Text

AN 2002:7196 USPAT2

TI Media milling

IN Verhoff, Frank H., Cincinnati, OH, United States

Snow, Robert A., West Chester, PA, United States

Pace, Gary W., Raleigh, NC, United States

PA SkyePharma Canada, Inc., Montreal, CANADA (non-U.S. corporation)

PI US 6604698 B2 20030812

CLM What is claimed is:

carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said.

5. The process of claim 1, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5, wherein the surface active substance is a **phospholipid** or mixture of **phospholipids**.

7. The process of claim 6, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, dimyristoylphosphatidylglycerol, and combinations thereof.

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007

L1 18 S (DRUG-LIPID COMPLEX?)

L2 18 S (DRUG-LIPID COMPLEX?)/AB,BI

FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007

L3 42 S (DRUG-LIPID COMPLEX?)

L4 3 S (DRUG-LIPID COMPLEX?)/CLM

L5 37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT

L6 1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT

L7 2 S L3 AND L5

L8 1 S L4 AND L6

L9 20 S PHOSPHILIPID?

L10 20 S PHOSPHILIPID?

L11 50032 S PHOSPHOLIPID?

L12 5315 S PHOSPHOLIPID?/CLM

L13 478 S L5 AND L11

L14 9 S L6 AND L12

=> s l3 and l11

L15 41 L3 AND L11

=> s 15 and 115
L16 2 L5 AND L15

=> d 1-2

L16 ANSWER 1 OF 2 USPATFULL on STN

Full Text

AN 2005:195837 USPATFULL
TI Wet-micro grinding
IN Fu, Shu-Wen, Hsin Chu City, CHINA
Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI US 2005169978 A1 20050804
AI US 2004-769118 A1 20040129 (10)
DT Utility
FS APPLICATION
LN.CNT 435
INCL INCLM: 424/450.000
INCLS: 514/034.000; 514/283.000; 514/449.000
NCL NCLM: 424/450.000
NCLS: 514/034.000; 514/283.000; 514/449.000
IC [7]
ICM A61K009-127
ICS A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 2 OF 2 USPATFULL on STN

Full Text

AN 95:13613 USPATFULL
TI Solid care therapeutic compositions and methods for making same
IN Chagnon, Mark S., Pelham, NH, United States
Ferris, John R., Newburyport, MA, United States
Hamilton, Tracy J., Salem, NH, United States
Rudd, Edwin A., Salem, NH, United States
Carter, Michelle J., Derry, NH, United States
PA Molecular Bioquest, Inc., Atkinson, NH, United States (U.S. corporation)
PI US 5389377 19950214
AI US 1992-958646 19921007 (7)
RLI Continuation-in-part of Ser. No. US 1992-894260, filed on 8 Jun 1992
which is a continuation-in-part of Ser. No. US 1990-566169, filed on 10
Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US
1989-455071, filed on 22 Dec 1989, now abandoned
DT Utility
FS Granted
LN.CNT 678
INCL INCLM: 424/450.000
INCLS: 424/490.000; 424/498.000; 424/600.000; 424/617.000; 424/630.000;
424/635.000; 424/639.000; 424/641.000; 424/644.000; 424/646.000;
424/650.000; 428/402.240
NCL NCLM: 424/450.000
NCLS: 424/490.000; 424/498.000; 424/600.000; 424/617.000; 424/630.000;
424/635.000; 424/639.000; 424/641.000; 424/644.000; 424/646.000;
424/650.000; 428/402.240
IC [6]
ICM A61K009-127
EXF 424/450; 424/417; 424/420; 424/600; 424/641; 424/617; 428/402.2;
428/402.24; 428/490; 428/498; 428/630; 428/635; 428/639; 428/644;
428/646; 428/650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic 2

L16 ANSWER 2 OF 2 USPATFULL on STN

SUMM

the hydrophobic and hydrophilic portions of the molecule
determines its physical properties in an aqueous environment. The uses
of natural **phospholipids** as additives include, for example, food
emulsifiers, cosmetics, industrial surfactants, and, and pharmaceutical
drug-delivery systems. U.S. Pat. Nos. 4,086,257, 4,097,502, 4,097,503,
4,145,410 and 4,159,988 disclose various modifications of the
polar-head-group region of natural **phospholipids** which lead to unique

physical properties.

SUMM . . . used to treat cancer and infectious diseases. The use of liposomes and other lipid structures, such as micro-emulsions, micelles, and **drug/lipid complexes**, for drug delivery has been widely proposed. Such lipid structures, and particularly liposomes, have the potential for providing controlled release.

SUMM . . . a lipid having two hydrocarbon chains, including acyl chains, and a polar head group. Included in this class are the **phospholipids**, such as phosphatidylcholine (PC), phosphatidic acid (PA), phosphatidylinositol (PI), sphingomyelin (SM), and the glycolipids, such as cerebroside and gangliosides.

DETD . . . collect the crystal between washes. The crystals are then milled to a more controlled particle size, for example, in a **ball mill**, under conditions sufficient to form 50 Angstroms or lower particle size. See, commonly assigned U.S. Pat. No. 5,071,076, and copending.

DETD . . . forming the inorganic core liposomes of the invention may be selected from a variety of vesicle forming lipids, typically including **phospholipids**, such as phosphatidylcholine (PC), phosphatidic (PA), phosphatidylinositol (PI), sphingomyelin (SM), and the glycolipids, such as cerebroside and gangliosides. The selection.

DETD The lipids may be either fluidic lipids, e.g. **phospholipids** whose acyl chains are relatively unsaturated, or more rigidifying membrane lipids, such as highly saturated **phospholipids**. Accordingly, the vesicle forming lipids may also be selected to achieve a selected degree of fluidity or rigidity to control.

DETD In a preferred embodiment, the vesicle forming lipid include those **phospholipids** in which the polar-head-group region is modified by the covalent attachment of polyalkylene ether polymers of various molecular weights. The attachment of the relatively hydrophilic polyalkylene ether polymer, particularly polyethylene oxide, alters the hydrophilic to hydrophobic balance within the **phospholipid** in order to give unique solubility to the **phospholipid** compound in an aqueous environment. See, e.g. U.S. Pat. No. 4,426,330. The polyalkyl ether lipid is preferably employed in the.

DETD . . . Fe₃O₄ acid equal to 2:1 weight percent. After mechanically milling the mixture for 1 to 1.5 hours on a **ball mill** with 4 mm glass media, the acid coated particles collapse around the media allowing for easy removal of water without.

DETD Absorbing a **phospholipid** onto the fatty acid coated particles was accomplished by addition of a synthetic polyethylene glycol terminated phosphatidyl ethanolamine to the.

DETD . . . include PEG-PE and PG, to a final concentration of charged lipids up to 40 mole percent, doxorubicin, and remainder neutral **phospholipids** or neutral **phospholipids** and cholesterol.

CLM What is claimed is:

5. The composition of claim 1 wherein the second amphipathic compound is selected from the group consisting of **phospholipids**, glycolipids, and mixtures thereof.

6. The composition of claim 5 wherein the **phospholipid** is selected from the group consisting of phosphatidylcholine, phosphatidic acid and phosphatidylinositol.

. . . group consisting of fatty acid compounds, and further coated with a second amphipathic compound selected from the group consisting of **phospholipids**, glycolipids, and mixtures thereof, characterized in that said solid core therapeutic composition has a size range of about 5-5000 nm.

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007

L1 18 S (DRUG-LIPID COMPLEX?)
L2 18 S (DRUG-LIPID COMPLEX?)/AB,BI

FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007

L3 42 S (DRUG-LIPID COMPLEX?)

L4 3 S (DRUG-LIPID COMPLEX?)/CLM
 L5 37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
 L6 1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
 L7 2 S L3 AND L5
 L8 1 S L4 AND L6
 L9 20 S PHOSPHILIPID?
 L10 20 S PHOSPHILIPID?
 L11 50032 S PHOSPHOLIPID?
 L12 5315 S PHOSPHOLIPID?/CLM
 L13 478 S L5 AND L11
 L14 9 S L6 AND L12
 L15 41 S L3 AND L11
 L16 2 S L5 AND L15

=> s (drug or active compound or active ingredient or active agent or compound)
 L17 975060 (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
 OR COMPOUND)

=> s (drug or active compound or active ingredient or active agent or compound)/clm
 L18 436672 (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
 OR COMPOUND)/CLM

=> s l11 and l17
 L19 45055 L11 AND L17

=> s l6 and l18
 L20 228 L6 AND L18

=> s l5 and l19
 L21 430 L5 AND L19

=> s l6 and l20
 L22 228 L6 AND L20

=> s l12 and l18
 L23 2412 L12 AND L18

=> s l6 and l23
 L24 7 L6 AND L23

=> d 1-7

L24 ANSWER 1 OF 7 USPATFULL on STN

Full Text

AN 2005:195837 USPATFULL
 TI Wet-micro grinding
 IN Fu, Shu-Wen, Hsin Chu City, CHINA
 Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
 Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
 Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
 PI US 2005169978 A1 20050804
 AI US 2004-769118 A1 20040129 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 435
 INCL INCLM: 424/450.000
 INCLS: 514/034.000; 514/283.000; 514/449.000
 NCL NCLM: 424/450.000
 NCLS: 514/034.000; 514/283.000; 514/449.000
 IC [7]
 ICM A61K009-127
 ICS A61K009-16; A61K009-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 2 OF 7 USPATFULL on STN

Full Text

AN 2004:15020 USPATFULL
 TI Method for producing powdery particle-reduced formulations with the aid
 of compressed gases
 IN Heidlas, Jorgen, Trostberg, GERMANY, FEDERAL REPUBLIC OF
 Ober, Martin, Altenmarkt, GERMANY, FEDERAL REPUBLIC OF
 Wiesmuller, Johann, Garching, GERMANY, FEDERAL REPUBLIC OF

PA Degussa AG, Trostberg, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
 PI US 6680284 B1 20040120
 WO 2001003671 20010118
 AI US 2002-30035 20020103 (10)
 WO 2000-EP6709 20000713
 PRAI DE 1999-19932648 19990713
 DE 1999-19960167 19991214
 DT Utility
 FS GRANTED
 LN.CNT 451
 INCL INCLM: 504/367.000
 INCLS: 424/489.000; 424/499.000; 424/500.000; 424/501.000; 424/502.000;
 514/959.000; 516/001.000; 516/114.000; 516/922.000; 516/928.000
 NCL NCLM: 504/367.000
 NCLS: 424/489.000; 424/499.000; 424/500.000; 424/501.000; 424/502.000;
 514/959.000; 516/001.000; 516/114.000; 516/922.000; 516/928.000
 IC [7]
 ICM A01N025-12
 ICS A61K009-16; B01J003-00
 EXF 424/489; 424/499; 424/500; 424/501; 424/502; 514/951; 504/367; 516/1;
 516/114; 516/922; 516/928
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 3 OF 7 USPATFULL on STN

Full Text

AN 2002:90568 USPATFULL
 TI Milled particles
 IN Verhoff, Frank, Cincinnati, OH, UNITED STATES
 Pace, Gary W., Winchester, MA, UNITED STATES
 Snow, Robert A., West Chester, PA, UNITED STATES
 Millar, Fay, Ladson, SC, UNITED STATES
 PI US 2002047058 A1 20020425
 US 6634576 B2 20031021
 AI US 2001-940864 A1 20010829 (9)
 PRAI US 2000-229042P 20000831 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4197
 INCL INCLM: 241/026.000
 INCLS: 424/489.000
 NCL NCLM: 241/021.000; 241/026.000
 NCLS: 241/184.000; 424/489.000
 IC [7]
 ICM B02C017-00
 ICS A61K009-14
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 4 OF 7 USPATFULL on STN

Full Text

AN 2002:7196 USPATFULL
 TI Media milling
 IN Verhoff, Frank H., Cincinnati, OH, UNITED STATES
 Snow, Robert A., West Chester, PA, UNITED STATES
 Pace, Gary W., Winchester, MA, UNITED STATES
 PI US 2002003179 A1 20020110
 US 6604698 B2 20030812
 AI US 2001-852054 A1 20010510 (9)
 PRAI US 2000-203366P 20000510 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2454
 INCL INCLM: 241/021.000
 INCLS: 241/172.000
 NCL NCLM: 241/021.000
 NCLS: 241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
 IC [7]
 ICM B02C017-16

L24 ANSWER 5 OF 7 USPATFULL on STN

Full Text

AN 1999:4081 USPATFULL

TI Pharmaceutical nanosuspensions for medicament administration as systems
 with increased saturation solubility and rate of solution
 IN Muller, Rainer H., Berlin, Germany, Federal Republic of
 Becker, Robert, Biberach, Germany, Federal Republic of
 Kruss, Bernd, Hochdorf, Germany, Federal Republic of
 Peters, Katrin, Berlin, Germany, Federal Republic of
 PA Medac Gesellschaft Fur Klinische Spezialpraparate, Hamburg, Germany,
 Federal Republic of (non-U.S. corporation)
 PI US 5858410 19990112
 WO 9614830 19960523
 AI US 1997-836305 19970619 (8)
 WO 1995-EP4401 19951109
 19970619 PCT 371 date
 19970619 PCT 102(e) date
 PRAI DE 1994-4440337 19941111
 DT Utility
 FS Granted
 LN.CNT 1289
 INCL INCLM: 424/489.000
 INCLS: 424/491.000; 424/493.000; 424/494.000; 424/495.000; 424/499.000
 NCL NCLM: 424/489.000
 NCLS: 424/491.000; 424/493.000; 424/494.000; 424/495.000; 424/499.000
 IC [6]
 ICM A61K009-14
 EXF 424/489; 424/491; 424/493; 424/494; 424/495; 424/499
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 6 OF 7 USPAT2 on STN

Full Text

AN 2002:90568 USPAT2
 TI Milled particles
 IN Verhoff, Frank, Cincinnati, OH, United States
 Pace, Gary W., Winchester, MA, United States
 Snow, Robert A., West Chester, PA, United States
 Millar, Fay, Ladson, SC, United States
 PA RTP Pharma Inc., Durham, NC, United States (U.S. corporation)
 PI US 6634576 B2 20031021
 AI US 2001-940864 20010829 (9)
 PRAI US 2000-229042P 20000831 (60)
 DT Utility
 FS GRANTED
 LN.CNT 4045
 INCL INCLM: 241/021.000
 INCLS: 241/184.000
 NCL NCLM: 241/021.000; 241/026.000
 NCLS: 241/184.000; 424/489.000
 IC [7]
 ICM B02C012-14
 EXF 241/21; 241/184; 241/171; 241/172; 241/23; 241/24.12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 7 OF 7 USPAT2 on STN

Full Text

AN 2002:7196 USPAT2
 TI Media milling
 IN Verhoff, Frank H., Cincinnati, OH, United States
 Snow, Robert A., West Chester, PA, United States
 Pace, Gary W., Raleigh, NC, United States
 PA SkyePharma Canada, Inc., Montreal, CANADA (non-U.S. corporation)
 PI US 6604698 B2 20030812
 AI US 2001-852054 20010510 (9)
 PRAI US 2000-203366P 20000510 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2454
 INCL INCLM: 241/021.000
 INCLS: 214/184.000
 NCL NCLM: 241/021.000
 NCLS: 241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
 IC [7]
 ICM B02C017-16
 ICS B02C019-12

EXF 214/184; 214/172; 214/171; 214/30; 214/21; 214/18; 214/57; 214/62;
424/450

=> d kwic 4-7

L24 ANSWER 4 OF 7 USPATFULL on STN

CLM What is claimed is:

carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said.

5. The process of claim 1 where the surface active substance is selected from the group consisting of a **phospholipid**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5 where the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine, . . .

9. The process of claim 7 where the pharmaceutical agent is a poorly water-soluble, an essentially water-insoluble **drug**, or an insoluble **drug**.

L24 ANSWER 5 OF 7 USPATFULL on STN

CLM What is claimed is:

1. **Drug** carrier comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 10 nm to . . . than 0.1 μ m (number distribution determined with a Coulter counter), and, when introduced into water, aqueous media and/or organic solvents, the **active compound** has an increased saturation solubility and an increased rate of dissolution compared with powders of the **active compound** prepared using an ultrasonic probe, a **ball mill** or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using a piston-gap. . .

7. Carrier according to claim 1, wherein the proportion of the internal or **drug** phase, based on the total weight of said carrier, is 0.1 to 30 wt. %.

8. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in water or aqueous solutions.

9. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in organic solvents.

10. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in water or aqueous solutions and in organic solvents.

11. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which have a moderate solubility in water or aqueous solutions and/or in organic solvents.

. . . esters, polyglycerol ethers and esters, lecithins, esters and ethers of sugars or sugar alcohols with fatty acids or fatty alcohols, **phospholipids** and sphingolipids, sterols, esters or ethers thereof and mixtures of these compounds.

. . . egg lecithin, soya lecithin or hydrogenated lecithin, mixtures thereof or mixtures of one or both lecithins with one or more **phospholipid** components, cholesterol, cholesterol palmitate, or stigmasterol.

22. Carrier according to claim 19, further comprising a **compound** selected from the group consisting of sugars or sugar alcohols, glucose, mannose, trehalose, mannitol and sorbitol.

28. Carrier according to claim 27, wherein, in the case of several active compounds, one **active compound** or several active compounds are dissolved or dispersed in another or several others, adsorbed onto the surface thereof or dispersed.
35. Process for the preparation of the **drug carrier** according to claim 1, wherein it is produced by using cavitation, wherein the **drug** or the **drug mixture** is ground to a powder, dispersed in a dispersing agent and forced under pressure through a gap, where cavitation.
36. Process for the preparation of the **drug carrier** according to claim 1, wherein it is produced by using shearing and impact forces, wherein the **drug** or the **drug mixture** is ground to a powder, dispersed in a dispersing agent and then ground in the wet state, in particular.
37. **Drug carrier** comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 40 nm to.
38. A method of making a **drug carrier** comprising the steps of: subjecting at least one solid therapeutically **active compound** dispersed in a solvent to high pressure homogenization in a piston-gap homogenizer to form particles having an average diameter, determined population being less than 0.1% (number distribution determined with a Coulter counter), without prior conversion into a melt, wherein said **active compound** is solid at room temperature and is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic.
39. **Drug carrier** comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 10 nm to. . . . than 0.1% (number distribution determined with a Coulter counter), and, when introduced into water, aqueous media and/or organic solvents, the **active compound** has an increased saturation solubility and an increased rate of dissolution compared with powders of the **active compound** prepared using an ultrasonic probe, a ball mill or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using cavitation or shearing and impact forces with introduction of a high amount of energy, and wherein said **active compound** comprises at least one **compound** selected from the group consisting of: analgesics, anaesthetics, antirheumatics, antiallergics, antibiotics, antiepileptics, antimycotics, calcium metabolism regulators, chemotherapeutics, corticoids, cytokines, cytostatics.
40. A **drug carrier** according to claim 39, wherein said **active compound** comprises an analgesic selected from the group consisting of morphine, codeine, piritramide, fentanyl, levomethadone, tramadol, diclofenac, ibuprofen, indomethacin, naproxen, and.
41. A **drug carrier** according to claim 39, wherein said **active compound** comprises an antiallergic selected from the group consisting of pheniramine, dimethindene, terfenadine, astemizole, loratidine, dosylamine and meclozine.
42. A **drug carrier** according to claim 39, wherein said **active compound** comprises an antibiotic selected from the group consisting of rifampicin, ethambutol and thiacetazone.
43. A **drug carrier** according to claim 39, wherein said **active compound** comprises an antiepileptic selected from the group consisting of clonazepam, mesuximide, phenyltoin, and valproic acid.
44. A **drug carrier** according to claim 39, wherein said **active compound** comprises an antimycotic selected from the group consisting of natamycin, amphotericin B, miconazole, clotrimazole, econazole, fenticonazole, bifonazole, ketoconazole and tolnaftate.
45. A **drug carrier** according to claim 39, wherein said **active compound** comprises a corticoide selected from the group consisting of aldosterone, fludrocortisone, betamethasone, dexamethasone, triamcinolone, fluocortolone, hydroxycortisone, prednisolone,

prednylidene, cloprednol and.

46. A **drug carrier** according to claim 39, wherein said **active compound** comprises a dermatic selected from the group consisting of tetracycline, erythromycin, framycetin, tyrothricin, fusidic acid, vidarabine, amcinonide, fluprednidene, alclometasone, clobetasol, . . .

47. A **drug carrier** according to claim 39, wherein said **active compound** comprises a hypnotic selected from the group consisting of cyclobarbitol, pentobarbital, methaqualone and benzodiazepines.

48. A **drug carrier** according to claim 39, wherein said **active compound** comprises an immunotherapeutic selected from the group consisting of azathioprine and ciclosporin.

49. A **drug carrier** according to claim 39, wherein said **active compound** comprises a local anaesthetic selected from the group consisting of butanilicaine, mepivacaine, bupivacaine, etidocaine, lidocaine, articaïne, oxybuprocaine, tetracaine, and benzocaine.

50. A **drug carrier** according to claim 39, wherein said **active compound** comprises a migraine agent selected from the group consisting of lisuride, methysergide, dihydroergotamine, and ergotamine.

51. A **drug carrier** according to claim 39, wherein said **active compound** comprises an anaesthetic selected from the group consisting of methohexital, propfol, etomidate, ketamine, thiopental, droperidol and fentanyl.

52. A **drug carrier** according to claim 39, wherein said **active compound** comprises dihydrotachysterol.

53. A **drug carrier** according to claim 39, wherein said **active compound** comprises an ophthalmic selected from the group consisting of cycloclrin, cyclopntolate, homatropine, trompcamide, pholedrine, edoxudine, aciclovir, acetazolamide, diclofenamide, carteolol, timolol, . . .

54. A **drug carrier** according to claim 39, wherein said **active compound** comprises a psychotropic selected from the group consisting of benzodiazepines.

55. A **drug carrier** according to claim 39, wherein said **active compound** comprises a sex hormone selected from the group consisting of anabolics, androgens, antiandrogens, gestagens, oestrogens and antioestrogens.

56. A **drug carrier** according to claim 39, wherein said **active compound** comprises a cytostatic or metastasis inhibitor selected from the group consisting of alkylating agents, antimetabolites, alkaloids, antibiotics, taxol and decarbazine.

57. A method of making a **drug carrier** comprising the steps of: subjecting at least one solid therapeutically **active compound** dispersed in a solvent to high pressure homogenization in a piston-gap homogenizer to form particles having an average diameter, determined . . . population being less than 0.1% (number distribution determined with a Coulter counter), without prior conversion into a melt, wherein said **active compound** is solid at room temperature and is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active compound** comprises at least one **compound** selected from the group consisting of: analgesics, anaesthetics, antirheumatics, antiallergics, antibiotics, antiepileptics, antimycotics, calcium metabolism regulators, chemotherapeutics, corticoids, cytokines, cytostatics, . . .

L24 ANSWER 6 OF 7 USPAT2 on STN

CLM What is claimed is:

. . . particulates of a first material of a desired size, said process comprising: a) providing to a milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of the first material to. . .

of claim 3, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

5. The process of claim 3, wherein the one or more than one surface active substance is a **phospholipid**.

6. The process of claim 5, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean.

9. The process of claim 8, wherein the pharmaceutical agent is a poorly water soluble or water insoluble **drug**.

14. The process of claim 2, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

15. The process of claim 2, wherein the one or more than one surface active substance is a **phospholipid**.

16. The process of claim 15, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean.

30. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid substrate.

1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at an exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L24 ANSWER 7 OF 7 USPAT2 on STN

CLM What is claimed is:

carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said.

5. The process of claim 1, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5, wherein the surface active substance is a **phospholipid** or mixture of **phospholipids**.

7. The process of claim 6, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, dimyristoylphosphatidylglycerol, and combinations thereof.

10. The process of claim 8, wherein the pharmaceutical agent is a poorly water-soluble **drug**, an essentially water-insoluble **drug**, or an insoluble **drug**.

=> d pi kwic 4-7

L24 ANSWER 4 OF 7 USPATFULL on STN

PI US 2002003179 A1 20020110
US 6604698 B2 20030812

CLM What is claimed is:

carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said.

5. The process of claim 1 where the surface active substance is selected

from the group consisting of a **phospholipid**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5 where the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine, . . .
9. The process of claim 7 where the pharmaceutical agent is a poorly water-soluble, an essentially water-insoluble **drug**, or an insoluble **drug**.

L24 ANSWER 5 OF 7 USPATFULL on STN
PI US 5858410 19990112
WO 9614830 19960523

CLM What is claimed is:

1. **Drug** carrier comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 10 nm to . . . than 0.1 μ m (number distribution determined with a Coulter counter), and, when introduced into water, aqueous media and/or organic solvents, the **active compound** has an increased saturation solubility and an increased rate of dissolution compared with powders of the **active compound** prepared using an ultrasonic probe, a ball mill or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using a piston-gap. . .
7. Carrier according to claim 1, wherein the proportion of the internal or **drug** phase, based on the total weight of said carrier, is 0.1 to 30 wt. %.

8. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in water or aqueous solutions.

9. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in organic solvents.

10. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in water or aqueous solutions and in organic solvents.

11. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which have a moderate solubility in water or aqueous solutions and/or in organic solvents.

. . . esters, polyglycerol ethers and esters, lecithins, esters and ethers of sugars or sugar alcohols with fatty acids or fatty alcohols, **phospholipids** and sphingolipids, sterols, esters or ethers thereof and mixtures of these compounds.

. . . egg lecithin, soya lecithin or hydrogenated lecithin, mixtures thereof or mixtures of one or both lecithins with one or more **phospholipid** components, cholesterol, cholesterol palmitate, or stigmasterol.

22. Carrier according to claim 19, further comprising a **compound** selected from the group consisting of sugars or sugar alcohols, glucose, mannose, trehalose, mannitol and sorbitol.

28. Carrier according to claim 27, wherein, in the case of several active compounds, one **active compound** or several active compounds are dissolved or dispersed in another or several others, adsorbed onto the surface thereof or dispersed.

35. Process for the preparation of the **drug** carrier according to claim 1, wherein it is produced by using cavitation, wherein the **drug** or the **drug** mixture is ground to a powder, dispersed in a dispersing agent and forced under pressure through a gap, where cavitation. . .

36. Process for the preparation of the **drug** carrier according to claim 1, wherein it is produced by using shearing and impact forces, wherein

the drug or the drug mixture is ground to a powder, dispersed in a dispersing agent and then ground in the wet state, in particular.

37. Drug carrier comprising particles of at least one therapeutically active compound which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said active ingredient is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 40 nm to.

38. A method of making a drug carrier comprising the steps of: subjecting at least one solid therapeutically active compound dispersed in a solvent to high pressure homogenization in a piston-gap homogenizer to form particles having an average diameter, determined population being less than 0.1% (number distribution determined with a Coulter counter), without prior conversion into a melt, wherein said active compound is solid at room temperature and is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic.

39. Drug carrier comprising particles of at least one therapeutically active compound which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said active ingredient is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 10 nm to. . . . than 0.1% (number distribution determined with a Coulter counter), and, when introduced into water, aqueous media and/or organic solvents, the active compound has an increased saturation solubility and an increased rate of dissolution compared with powders of the active compound prepared using an ultrasonic probe, a ball mill or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using cavitation or shearing and impact forces with introduction of a high amount of energy, and wherein said active compound comprises at least one compound selected from the group consisting of: analgesics, anaesthetics, antirheumatics, antiallergics, antibiotics, antiepileptics, antimycotics, calcium metabolism regulators, chemotherapeutics, corticoids, cytokines, cytostatics,

40. A drug carrier according to claim 39, wherein said active compound comprises an analgesic selected from the group consisting of morphine, codeine, piritramide, fentanyl, levomethadone, tramadol, diclofenac, ibuprofen, indomethacin, naproxen, and.

41. A drug carrier according to claim 39, wherein said active compound comprises an antiallergic selected from the group consisting of pheniramine, dimethindene, terfenadine, astemizole, loratidine, dosylamine and meclozine.

42. A drug carrier according to claim 39, wherein said active compound comprises an antibiotic selected from the group consisting of rifampicin, ethambutol and thiacetazone.

43. A drug carrier according to claim 39, wherein said active compound comprises an antiepileptic selected from the group consisting of clonazepam, mesuximide, phenyltoin, and valproic acid.

44. A drug carrier according to claim 39, wherein said active compound comprises an antimycotic selected from the group consisting of natamycin, amphotericin B, miconazole, clotrimazole, econazole, fenticonazole, bifonazole, ketoconazole and tolnaftate.

45. A drug carrier according to claim 39, wherein said active compound comprises a corticoid selected from the group consisting of aldosterone, fludrocortisone, betamethasone, dexamethasone, triamcinolone, fluocortolone, hydroxycortisone, prednisolone, prednylidene, cloprednol and.

46. A drug carrier according to claim 39, wherein said active compound comprises a dermatic selected from the group consisting of tetracycline, erythromycin, framycin, tyrothricin, fusidic acid, vidarabine, amcinonide, fluprednidene, alclometasone, clobetasol,

47. A drug carrier according to claim 39, wherein said active compound comprises a hypnotic selected from the group consisting of cyclobarbitol, pentobarbitol, methaqualone and benzodiazepines.

48. A drug carrier according to claim 39, wherein said active compound comprises an immunotherapeutic selected from the group

consisting of azathioprine and ciclosporin.

49. A drug carrier according to claim 39, wherein said **active compound** comprises a local anaesthetic selected from the group consisting of butanilicaine, mepivacaine, bupivacaine, etidocaine, lidocaine, articaïne, oxybuprocaine, tetracaine, and benzocaine.

50. A drug carrier according to claim 39, wherein said **active compound** comprises a migraine agent selected from the group consisting of lisuride, methysergide, dihydroergotamine, and ergotamine.

51. A drug carrier according to claim 39, wherein said **active compound** comprises an anaesthetic selected from the group consisting of methohexital, propfol, etomidate, ketamine, thiopental, droperidol and fentanyl.

52. A drug carrier according to claim 39, wherein said **active compound** comprises dihydrotachysterol.

53. A drug carrier according to claim 39, wherein said **active compound** comprises an ophthalmic selected from the group consisting of cycloclonin, cyclopentolate, homatropine, trompcamide, pholedrine, edoxudine, aciclovir, acetazolamide, diclofenamide, carteolol, timolol,.

54. A drug carrier according to claim 39, wherein said **active compound** comprises a psychotropic selected from the group consisting of benzodiazepines.

55. A drug carrier according to claim 39, wherein said **active compound** comprises a sex hormone selected from the group consisting of anabolics, androgens, antiandrogens, gestagens, oestrogens and antioestrogens.

56. A drug carrier according to claim 39, wherein said **active compound** comprises a cytostatic or metastasis inhibitor selected from the group consisting of alkylating agents, antimetabolites, alkaloids, antibiotics, taxol and decarbazine.

57. A method of making a drug carrier comprising the steps of: subjecting at least one solid therapeutically **active compound** dispersed in a solvent to high pressure homogenization in a piston-gap homogenizer to form particles having an average diameter, determined, population being less than 0.1% (number distribution determined with a Coulter counter), without prior conversion into a melt, wherein said **active compound** is solid at room temperature and is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active compound** comprises at least one **compound** selected from the group consisting of: analgesics, anaesthetics, antirheumatics, antiallergics, antibiotics, antiepileptics, antimycotics, calcium metabolism regulators, chemotherapeutics, corticoids, cytokines, cytostatics, . . .

L24 ANSWER 6 OF 7 USPAT2 on STN
PI US 6634576 B2 20031021
CLM What is claimed is:

. . . particulates of a first material of a desired size, said process comprising: a) providing to a milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of the first material to. . .
of claim 3, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

5. The process of claim 3, wherein the one or more than one surface active substance is a **phospholipid**.

6. The process of claim 5, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy

phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean.

9. The process of claim 8, wherein the pharmaceutical agent is a poorly water soluble or water insoluble **drug**.

14. The process of claim 2, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

15. The process of claim 2, wherein the one or more than one surface active substance is a **phospholipid**.

16. The process of claim 15, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean.

30. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid substrate.

1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at an exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L24 ANSWER 7 OF 7 USPAT2 on STN

PI US 6604698 B2 20030812

CLM What is claimed is:

carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said.

5. The process of claim 1, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5, wherein the surface active substance is a **phospholipid** or mixture of **phospholipids**.

7. The process of claim 6, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, dimyristoylphosphatidylglycerol, and combinations thereof.

10. The process of claim 8, wherein the pharmaceutical agent is a poorly water-soluble **drug**, an essentially water-insoluble **drug**, or an insoluble **drug**.

=> s pharmaceutical agent

L25 7 PHARMACETICAL AGENT

=> s pharmaceutical agent

L26 12656 PHARMACEUTICAL AGENT

=> s pharmaceutical agent/clm

L27 1762 PHARMACEUTICAL AGENT/CLM

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007

L1 18 S (DRUG-LIPID COMPLEX?)

L2 18 S (DRUG-LIPID COMPLEX?)/AB,BI

FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007

L3 42 S (DRUG-LIPID COMPLEX?)

L4 3 S (DRUG-LIPID COMPLEX?)/CLM

L5 37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
 L6 1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
 L7 2 S L3 AND L5
 L8 1 S L4 AND L6
 L9 20 S PHOSPHILIPID?
 L10 20 S PHOSPHILIPID?
 L11 50032 S PHOSPHOLIPID?
 L12 5315 S PHOSPHOLIPID?/CLM
 L13 478 S L5 AND L11
 L14 9 S L6 AND L12
 L15 41 S L3 AND L11
 L16 2 S L5 AND L15
 L17 975060 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
 L18 436672 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
 L19 45055 S L11 AND L17
 L20 228 S L6 AND L18
 L21 430 S L5 AND L19
 L22 228 S L6 AND L20
 L23 2412 S L12 AND L18
 L24 7 S L6 AND L23
 L25 7 S PHARMACETICAL AGENT
 L26 12656 S PHARMACEUTICAL AGENT
 L27 1762 S PHARMACEUTICAL AGENT/CLM

=> s l11 and l26

L28 2845 L11 AND L26

=> s l12 amd l27

MISSING OPERATOR L12 AMD

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l12 and l27

L29 64 L12 AND L27

=> s l5 and l28

L30 51 L5 AND L28

=> s l6 and l29

L31 4 L6 AND L29

=> d 1-4

L31 ANSWER 1 OF 4 USPATFULL on STN

Full Text

AN 2002:90568 USPATFULL
 TI Milled particles
 IN Verhoff, Frank, Cincinnati, OH, UNITED STATES
 Pace, Gary W., Winchester, MA, UNITED STATES
 Snow, Robert A., West Chester, PA, UNITED STATES
 Millar, Fay, Ladson, SC, UNITED STATES
 PI US 2002047058 A1 20020425
 US 6634576 B2 20031021
 AI US 2001-940864 A1 20010829 (9)
 PRAI US 2000-229042P 20000831 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4197
 INCL INCLM: 241/026.000
 INCLS: 424/489.000
 NCL NCLM: 241/021.000; 241/026.000
 NCLS: 241/184.000; 424/489.000
 IC [7]
 ICM B02C017-00
 ICS A61K009-14
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 2 OF 4 USPATFULL on STN

Full Text

AN 2002:7196 USPATFULL
 TI Media milling
 IN Verhoff, Frank H., Cincinnati, OH, UNITED STATES

Snow, Robert A., West Chester, PA, UNITED STATES
Pace, Gary W., Winchester, MA, UNITED STATES
PI US 2002003179 A1 20020110
US 6604698 B2 20030812
AI US 2001-852054 A1 20010510 (9)
PRAI US 2000-203366P 20000510 (60)
DT Utility
FS APPLICATION
LN.CNT 2454
INCL INCLM: 241/021.000
INCLS: 241/172.000
NCL NCLM: 241/021.000
NCLS: 241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
IC [7]
ICM B02C017-16

L31 ANSWER 3 OF 4 USPAT2 on STN

Full Text

AN 2002:90568 USPAT2
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, United States
Pace, Gary W., Winchester, MA, United States
Snow, Robert A., West Chester, PA, United States
Millar, Fay, Ladson, SC, United States
PA RTP Pharma Inc., Durham, NC, United States (U.S. corporation)
PI US 6634576 B2 20031021
AI US 2001-940864 20010829 (9)
PRAI US 2000-229042P 20000831 (60)
DT Utility
FS GRANTED
LN.CNT 4045
INCL INCLM: 241/021.000
INCLS: 241/184.000
NCL NCLM: 241/021.000; 241/026.000
NCLS: 241/184.000; 424/489.000
IC [7]
ICM B02C012-14
EXF 241/21; 241/184; 241/171; 241/172; 241/23; 241/24.12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 4 OF 4 USPAT2 on STN

Full Text

AN 2002:7196 USPAT2
TI Media milling
IN Verhoff, Frank H., Cincinnati, OH, United States
Snow, Robert A., West Chester, PA, United States
Pace, Gary W., Raleigh, NC, United States
PA SkyePharma Canada, Inc., Montreal, CANADA (non-U.S. corporation)
PI US 6604698 B2 20030812
AI US 2001-852054 20010510 (9)
PRAI US 2000-203366P 20000510 (60)
DT Utility
FS GRANTED
LN.CNT 2454
INCL INCLM: 241/021.000
INCLS: 214/184.000
NCL NCLM: 241/021.000
NCLS: 241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
IC [7]
ICM B02C017-16
ICS B02C019-12
EXF 214/184; 214/172; 214/171; 214/30; 214/21; 214/18; 214/57; 214/62;
424/450

=> d ti pi kwic 1-4

L31 ANSWER 1 OF 4 USPATFULL on STN

TI Milled particles
PI US 2002047058 A1 20020425
US 6634576 B2 20031021
CLM What is claimed is:

first material of a desired size, said process comprising the steps of: a) providing to the milling chamber of a media mill a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said media mill to grind said solid substrate and degrade at least a portion of said milling bodies of first material to produce.

material, a solid cosmetic ingredient, a solid support material, a solid toner material, a solid grinding material, and a solid pharmaceutical agent.

5. The process of claim 1, wherein the solid substrate is a pharmaceutical agent.

6. The process of claim 5, wherein the pharmaceutical agent is a poorly water soluble or water insoluble drug.

7. The process of claim 5, wherein the pharmaceutical agent is selected from the group consisting of an anesthetic agent, an ace inhibiting agent, an antithrombotic agent, an anti-allergic agent, insulin, an interferon, a lactation inhibiting agent, a lipid-lowering agent, a lymphokine, a neurologic agent, a prostacyclin, a prostaglandin, a psycho-pharmaceutical agent, a protease inhibitor, a magnetic resonance diagnostic imaging agent, a reproductive control hormone, a sedative agent, a sex hormone, a.

8. The process of claim 5, wherein the pharmaceutical agent is selected from the group consisting of fenofibrate, nitrocamptothecin, and cyclosporin.

11. The process of claim 2 or 3, wherein the surface active substance is selected from the group consisting of phospholipids, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

12. The process of claim 2 or 3, wherein the surface active substance is a phospholipid.

13. The process of claim 12, wherein the phospholipid is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine.

27. The process of claim 1, wherein the media mill is maintained at a temperature below the melting point of the solid.

1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the media mill, a separator at the exit port in the media mill, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L31 ANSWER 2 OF 4 USPATFULL on STN

TI Media milling

PI US 2002003179 A1 20020110

US 6604698 B2 20030812

CLM What is claimed is:

carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a media mill and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said.

5. The process of claim 1 where the surface active substance is selected from the group consisting of a phospholipid, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5 where the phospholipid is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine, pigment, a solid photographic material, a solid cosmetic ingredient, a solid support material, a solid toner material, and a solid pharmaceutical agent.

8. The process of claim 7 where the pharmaceutical agent is selected from the group consisting of a therapeutic agent and a diagnostic

imaging agent.

9. The process of claim 7 where the **pharmaceutical agent** is a poorly water-soluble, an essentially water-insoluble drug, or an insoluble drug.

10. The process of claim 7 where the **pharmaceutical agent** is selected from the group consisting of anesthetic agents, ace inhibiting agents, antithrombotic agents, anti-allergic agents, antibacterial agents, antibiotic agents,

11. The process of claim 7 wherein the **pharmaceutical agent** is selected from the group consisting of albendazole, albendazole sulfoxide, alfaxalone, acetyl digoxin, acyclovir, acyclovir analogs, alprostadil, aminofostin, anipamil, antithrombin. . . .

12. The process of claim 7 wherein the **pharmaceutical agent** is selected from the group consisting of acyclovir, alprazolam, altretamine, amiloride, amiodarone, benztropine mesylate, bupropion, cabergoline, candesartan, cerivastatin, chlorpromazine, ciprofloxacin, . .

L31 ANSWER 3 OF 4 USPAT2 on STN

TI Milled particles

PI US 6634576 B2 20031021

CLM What is claimed is:

. . . . particulates of a first material of a desired size, said process comprising: a) providing to a milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of the first material to. . . .

. . . . of claim 3, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

5. The process of claim 3, wherein the one or more than one surface active substance is a **phospholipid**.

6. The process of claim 5, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . . .

. . . . material, a solid cosmetic ingredient, a solid support material, a solid toner material, a solid grinding material, and a solid **pharmaceutical agent**.

8. The process of claim 1, wherein the solid substrate is a **pharmaceutical agent**.

9. The process of claim 8, wherein the **pharmaceutical agent** is a poorly water soluble or water insoluble drug.

10. The process of claim 8, wherein the **pharmaceutical agent** is selected from the group consisting of an anesthetic agent, an ace inhibiting agent, an antithrombotic agent, an anti-allergic agent,
. . . . insulin, an interferon, a lactation inhibiting agent, a lipid-lowering agent, a lymphokine, a neurologic agent, a prostacyclin, a prostaglandin, a psycho-**pharmaceutical agent**, a protease inhibitor, a magnetic resonance diagnostic imaging agent, a reproductive control hormone, a sedative agent, a sex hormone, a. . . .

11. The process of claim 8, wherein the **pharmaceutical agent** is selected from the group consisting of fenofibrate, nitrocamptothecin, and cyclosporin.

. . . . of claim 2, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

15. The process of claim 2, wherein the one or more than one surface active substance is a **phospholipid**.

16. The process of claim 15, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . . .
30. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid substrate.

. . . 1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at an exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L31 ANSWER 4 OF 4 USPAT2 on STN

TI Media milling

PI US 6604698 B2 20030812

CLM What is claimed is:

. . . carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said. . . .

5. The process of claim 1, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5, wherein the surface active substance is a **phospholipid** or mixture of **phospholipids**.

7. The process of claim 6, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, dimyristoylphosphatidylglycerol, and combinations thereof.

. . . pigment, a solid photographic material, a solid cosmetic ingredient, a solid support material, a solid toner material, and a solid **pharmaceutical agent**.

9. The process of claim 8, wherein the **pharmaceutical agent** is a therapeutic agent or a diagnostic imaging agent.

10. The process of claim 8, wherein the **pharmaceutical agent** is a poorly water-soluble drug, an essentially water-insoluble drug, or an insoluble drug.

11. The process of claim 9, wherein the **pharmaceutical agent** is selected from the group consisting of anesthetic agents, ace inhibiting agents, antithrombotic agents, anti-allergic agents, antibacterial agents, antibiotic agents,

12. The process of claim 8, wherein the **pharmaceutical agent** is selected from the group consisting of albendazole, albendazole sulfoxide, alfaxalone, acetyl digoxin, acyclovir, acyclovir analogs, aiprostadil, aminofostin, anipamil, antithrombin. . . .

13. The process of claim 8, wherein the **pharmaceutical agent** is selected from the group consisting of acyclovir, alprazolam, altretamine, amiloride, amiodarone, benztropine mesylate, bupropion, cabergoline, candesartan, cerivastatin, chlorpromazine, ciprofloxacin,

=> s dispersion mill

L32 353 DISPERSION MILL

=> s dispersion mill/clm

L33 15 DISPERSION MILL/CLM

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007

L1 18 S (DRUG-LIPID COMPLEX?)
 L2 18 S (DRUG-LIPID COMPLEX?)/AB,BI

FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007

L3 42 S (DRUG-LIPID COMPLEX?)
 L4 3 S (DRUG-LIPID COMPLEX?)/CLM
 L5 37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
 L6 1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
 L7 2 S L3 AND L5
 L8 1 S L4 AND L6
 L9 20 S PHOSPHILIPID?
 L10 20 S PHOSPHILIPID?
 L11 50032 S PHOSPHOLIPID?
 L12 5315 S PHOSPHOLIPID?/CLM
 L13 478 S L5 AND L11
 L14 9 S L6 AND L12
 L15 41 S L3 AND L11
 L16 2 S L5 AND L15
 L17 975060 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
 L18 436672 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
 L19 45055 S L11 AND L17
 L20 228 S L6 AND L18
 L21 430 S L5 AND L19
 L22 228 S L6 AND L20
 L23 2412 S L12 AND L18
 L24 7 S L6 AND L23
 L25 7 S PHARMACETICAL AGENT
 L26 12656 S PHARMACEUTICAL AGENT
 L27 1762 S PHARMACEUTICAL AGENT/CLM
 L28 2845 S L11 AND L26
 L29 64 S L12 AND L27
 L30 51 S L5 AND L28
 L31 4 S L6 AND L29
 L32 353 S DISPERSION MILL
 L33 15 S DISPERSION MILL/CLM

=> s l11 and l32
 L34 41 L11 AND L32

=> s l12 and l33
 L35 1 L12 AND L33

=> d

L35 ANSWER 1 OF 1 USPATFULL on STN

Full Text

AN 2005:195837 USPATFULL
 TI Wet-micro grinding
 IN Fu, Shu-Wen, Hsin Chu City, CHINA
 Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
 Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
 Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
 PI US 2005169978 A1 20050804
 AI US 2004-769118 A1 20040129 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 435
 INCL INCLM: 424/450.000
 INCLS: 514/034.000; 514/283.000; 514/449.000
 NCL NCLM: 424/450.000
 NCLS: 514/034.000; 514/283.000; 514/449.000
 IC [7]
 ICM A61K009-127
 ICS A61K009-16; A61K009-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l34 1-41

L34 ANSWER 1 OF 41 USPATFULL on STN

Full Text

AN 2007:75024 USPATFULL

TI Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
 IN Liversidge, Gary, West Chester, PA, UNITED STATES
 Jenkins, Scott, Downingtown, PA, UNITED STATES
 Wertz, Christian F., Lansdale, PA, UNITED STATES
 Bosch, H. William, Bryn Mawr, PA, UNITED STATES
 PA Elan Pharma International Limited (U.S. corporation)
 PI US 2007065374 A1 20070322
 AI US 2006-376553 A1 20060316 (11)
 PRAI US 2005-662339P 20050316 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3132
 INCL INCLM: 424/046.000
 INCLS: 424/489.000; 514/312.000; 514/393.000; 514/171.000
 NCL NCLM: 424/046.000
 NCLS: 424/489.000; 514/171.000; 514/312.000; 514/393.000
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 2 OF 41 USPATFULL on STN

Full Text

AN 2007:48227 USPATFULL
 TI Nanoparticulate benidipine compositions
 IN Liversidge, Gary G., West Chester, PA, UNITED STATES
 Jenkins, Scott, Downingtown, PA, UNITED STATES
 PA Elan Pharma International, Limited (U.S. corporation)
 PI US 2007042049 A1 20070222
 AI US 2006-446589 A1 20060605 (11)
 PRAI US 2005-687145P 20050603 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1802
 INCL INCLM: 424/489.000
 INCLS: 977/906.000
 NCL NCLM: 424/489.000
 NCLS: 977/906.000
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 3 OF 41 USPATFULL on STN

Full Text

AN 2007:17120 USPATFULL
 TI Treatment of eye disorders with sirtuin modulators
 IN Milburn, Michael, Cary, NC, UNITED STATES
 Westphal, Christoph H., Brookline, MA, UNITED STATES
 Dipp, Michelle, Cambridge, MA, UNITED STATES
 PA Sirtris Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02139 (U.S. corporation)
 PI US 2007014833 A1 20070118
 AI US 2005-374278 A1 20051028 (11)
 PRAI US 2005-667179P 20050330 (60)
 US 2005-684252P 20050525 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6021
 INCL INCLM: 424/427.000
 INCLS: 514/058.000; 514/043.000; 514/733.000; 977/906.000
 NCL NCLM: 424/427.000
 NCLS: 514/043.000; 514/058.000; 514/733.000; 977/906.000
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 4 OF 41 USPATFULL on STN

Full Text

AN 2007:4434 USPATFULL
 TI Nanoparticulate clopidogrel formulations
 IN Liversidge, Gary G., West Chester, PA, UNITED STATES
 Jenkins, Scott, Downingtown, PA, UNITED STATES
 PA Elan Pharma International Limited (U.S. corporation)
 PI US 2007003628 A1 20070104
 AI US 2006-430180 A1 20060509 (11)
 PRAI US 2005-679398P 20050510 (60)
 DT Utility
 FS APPLICATION

LN.CNT 1856
INCL INCLM: 424/489.000
INCLS: 977/906.000
NCL NCLM: 424/489.000
NCLS: 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 5 OF 41 USPATFULL on STN

Full Text

AN 2006:340319 USPATFULL
TI Treatment of eye disorders with sirtuin modulators
IN Milburn, Michael, Cary, NC, UNITED STATES
Westphal, Christoph H., Brookline, MA, UNITED STATES
Livingston, David J., Barrington, RI, UNITED STATES
Elliott, Peter, Marlborough, MA, UNITED STATES
Lambert, Philip, Northborough, MA, UNITED STATES
Normington, Karl D., Acton, MA, UNITED STATES
PI US 2006292099 A1 20061228
AI US 2006-440584 A1 20060524 (11)
PRAI US 2005-684252P 20050525 (60)
US 2006-788358P 20060330 (60)
DT Utility
FS APPLICATION
LN.CNT 6624
INCL INCLM: 424/070.100
NCL NCLM: 424/070.100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 6 OF 41 USPATFULL on STN

Full Text

AN 2006:288153 USPATFULL
TI Nanoparticulate lipase inhibitor formulations
IN Liversidge, Gary G., West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International, Limited (U.S. corporation)
PI US 2006246141 A1 20061102
AI US 2006-402257 A1 20060412 (11)
PRAI US 2005-670416P 20050412 (60)
DT Utility
FS APPLICATION
LN.CNT 2441
INCL INCLM: 424/489.000
INCLS: 514/449.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/449.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 7 OF 41 USPATFULL on STN

Full Text

AN 2006:253903 USPATFULL
TI Nanoparticulate corticosteroid and antihistamine formulations
IN Liversidge, Gary, West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
Bosch, H. William, Bryn Mawr, PA, UNITED STATES
Wertz, Christian F., Lansdale, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006216353 A1 20060928
AI US 2006-387068 A1 20060323 (11)
PRAI US 2005-664359P 20050323 (60)
DT Utility
FS APPLICATION
LN.CNT 2578
INCL INCLM: 424/489.000
INCLS: 514/171.000; 977/906.000; 514/217.050; 424/046.000
NCL NCLM: 424/489.000
NCLS: 424/046.000; 514/171.000; 514/217.050; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 8 OF 41 USPATFULL on STN

Full Text

AN 2006:247250 USPATFULL
TI Nanoparticulate bisphosphonate compositions

IN Liversidge, Gary G., West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006210639 A1 20060921
AI US 2006-377650 A1 20060317 (11)
PRAI US 2005-662693P 20050317 (60)
DT Utility
FS APPLICATION
LN.CNT 2243
INCL INCLM: 424/489.000
INCLS: 514/102.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/102.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 9 OF 41 USPATFULL on STN

Full Text

AN 2006:247249 USPATFULL
TI Injectable compositions of nanoparticulate immunosuppressive compounds
IN Liversidge, Gary G., West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006210638 A1 20060921
AI US 2006-376554 A1 20060316 (11)
PRAI US 2005-662692P 20050317 (60)
DT Utility
FS APPLICATION
LN.CNT 2139
INCL INCLM: 424/489.000
INCLS: 514/291.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/291.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 10 OF 41 USPATFULL on STN

Full Text

AN 2006:247233 USPATFULL
TI Surface modified particulate compositions of biologically active substances
IN Pace, Gary W., Winchester, MA, UNITED STATES
Mishra, Awadhesh K., Verdun, CANADA
Snow, Robert A., West Chester, PA, UNITED STATES
PA Skyepharma Canada Inc. (U.S. corporation)
PI US 2006210622 A1 20060921
AI US 2005-272902 A1 20051114 (11)
RLI Continuation of Ser. No. US 2000-667328, filed on 21 Sep 2000, ABANDONED
PRAI US 1999-154964P 19990921 (60)
DT Utility
FS APPLICATION
LN.CNT 1297
INCL INCLM: 424/456.000
INCLS: 424/469.000
NCL NCLM: 424/456.000
NCLS: 424/469.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 11 OF 41 USPATFULL on STN

Full Text

AN 2006:240143 USPATFULL
TI Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
IN Liversidge, Gary, Westchester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006204588 A1 20060914
AI US 2006-372227 A1 20060310 (11)
PRAI US 2005-660229P 20050310 (60)
DT Utility
FS APPLICATION
LN.CNT 2333
INCL INCLM: 424/490.000
INCLS: 977/906.000

NCL NCLM: 424/490.000
NCLS: 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 12 OF 41 USPATFULL on STN

Full Text

AN 2006:233444 USPATFULL
TI Aerosol and injectable formulations of nanoparticulate benzodiazepine
IN Liversidge, Gary, West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006198896 A1 20060907
AI US 2006-354249 A1 20060215 (11)
PRAI US 2005-653034P 20050215 (60)
DT Utility
FS APPLICATION
LN.CNT 2516
INCL INCLM: 424/489.000
INCLS: 514/221.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/221.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 13 OF 41 USPATFULL on STN

Full Text

AN 2006:221286 USPATFULL
TI Nanoparticulate formulations of docetaxel and analogues thereof
IN Liversidge, Gary, Westchester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
Liversidge, Elaine, Westchester, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006188566 A1 20060824
AI US 2006-361055 A1 20060224 (11)
PRAI US 2005-655934P 20050224 (60)
DT Utility
FS APPLICATION
LN.CNT 2814
INCL INCLM: 424/451.000
INCLS: 549/510.000; 514/449.000; 977/907.000; 977/906.000; 424/464.000
NCL NCLM: 424/451.000
NCLS: 424/464.000; 514/449.000; 549/510.000; 977/906.000; 977/907.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 14 OF 41 USPATFULL on STN

Full Text

AN 2006:188330 USPATFULL
TI Nanoparticulate tacrolimus formulations
IN Jenkins, Scott, Downingtown, PA, UNITED STATES
Liversidge, Gary, West Chester, PA, UNITED STATES
Liversidge, Elaine, West Chester, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006159766 A1 20060720
AI US 2005-300592 A1 20051215 (11)
PRAI US 2004-636817P 20041215 (60)
US 2005-731869P 20051101 (60)
DT Utility
FS APPLICATION
LN.CNT 2352
INCL INCLM: 424/489.000
INCLS: 514/291.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/291.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 15 OF 41 USPATFULL on STN

Full Text

AN 2006:188193 USPATFULL
TI Nanoparticulate benzothiophene formulations
IN Liversidge, Gary, West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006159628 A1 20060720

AI US 2005-292314 A1 20051202 (11)
 PRAI US 2004-633003P 20041203 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2268
 INCL INCLM: 424/046.000
 INCLS: 514/320.000; 977/906.000; 424/489.000
 NCL NCLM: 424/046.000
 NCLS: 424/489.000; 514/320.000; 977/906.000
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 16 OF 41 USPATFULL on STN

Full Text

AN 2006:182514 USPATFULL
 TI Injectable nanoparticulate olanzapine formulations
 IN Liversidge, Gary, West Chester, PA, UNITED STATES
 Jenkins, Scott, Downingtown, PA, UNITED STATES
 Liversidge, Elaine Merisko, West Chester, PA, UNITED STATES
 PA Elan Pharma International Limited (U.S. corporation)
 PI US 2006154918 A1 20060713
 AI US 2005-274887 A1 20051116 (11)
 PRAI US 2004-628748P 20041116 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1575
 INCL INCLM: 514/220.000
 INCLS: 977/906.000
 NCL NCLM: 514/220.000
 NCLS: 977/906.000
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 17 OF 41 USPATFULL on STN

Full Text

AN 2005:195837 USPATFULL
 TI Wet-micro grinding
 IN Fu, Shu-Wen, Hsin Chu City, CHINA
 Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
 Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
 Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
 PI US 2005169978 A1 20050804
 AI US 2004-769118 A1 20040129 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 435
 INCL INCLM: 424/450.000
 INCLS: 514/034.000; 514/283.000; 514/449.000
 NCL NCLM: 424/450.000
 NCLS: 514/034.000; 514/283.000; 514/449.000
 IC [7]
 ICM A61K009-127
 ICS A61K009-16; A61K009-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 18 OF 41 USPATFULL on STN

Full Text

AN 2005:10449 USPATFULL
 TI Methods and compositions that enhance bioavailability of coenzyme-Q10
 IN Parkhideh, Daryoush, Old Field, NY, UNITED STATES
 PA NBTY, Inc., Bohemia, NY (U.S. corporation)
 PI US 2005008581 A1 20050113
 AI US 2004-840423 A1 20040507 (10)
 PRAI US 2003-476197P 20030606 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1002
 INCL INCLM: 424/046.000
 INCLS: 424/094.100; 514/680.000
 NCL NCLM: 424/046.000
 NCLS: 424/094.100; 514/680.000; 977/801.000
 IC [7]
 ICM A61L009-04
 ICS A61K009-14; A61K038-43; A61K031-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 19 OF 41 USPATFULL on STN

Full Text

AN 2004:334304 USPATFULL
TI Cyclooxygenase-2 inhibitor compositions having rapid onset of
therapeutic effect
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
Hageman, Michael J., Portage, IL, UNITED STATES
Haskell, Royal J., Kalamazoo, MI, UNITED STATES
PI US 2004265382 A1 20041230
US 7172769 B2 20070206
AI US 2002-31898 A1 20020730 (10)
WO 2000-US32434 20001206
PRAI US 1999-169856P 19991209 (60)
DT Utility
FS APPLICATION
LN.CNT 1963
INCL INCLM: 424/469.000
INCLS: 514/406.000; 424/452.000
NCL NCLM: 424/501.000; 424/469.000
NCLS: 424/489.000; 424/452.000; 514/406.000
IC [7]
ICM A61K009-26
ICS A61K031-415; A61K009-48

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 20 OF 41 USPATFULL on STN

Full Text

AN 2004:76129 USPATFULL
TI Nanoparticulate beclomethasone dipropionate compositions
IN Wood, Ray W., King of Prussia, PA, UNITED STATES
DeCastro, Lan, King of Prussia, PA, UNITED STATES
Bosch, H. William, Bryn Mawr, PA, UNITED STATES
PA Elan Pharma International Ltd. (U.S. corporation)
PI US 2004057905 A1 20040325
AI US 2003-667472 A1 20030923 (10)
RLI Continuation of Ser. No. US 2000-577489, filed on 25 May 2000, PENDING
Division of Ser. No. US 1997-948216, filed on 9 Oct 1997, GRANTED, Pat.
No. US 6264922 Continuation of Ser. No. US 1996-589681, filed on 19 Jan
1996, ABANDONED Continuation-in-part of Ser. No. US 1995-394103, filed
on 24 Feb 1995, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 989
INCL INCLM: 424/009.453
INCLS: 424/045.000
NCL NCLM: 424/009.453
NCLS: 424/045.000
IC [7]
ICM A61K049-04
ICS A61L009-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 21 OF 41 USPATFULL on STN

Full Text

AN 2003:92740 USPATFULL
TI Cyclooxygenase-2 inhibitor compositions having rapid onset of
therapeutic effect
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
Hageman, Michael J., Portage, MI, UNITED STATES
Haskell, Royal J., Kalamazoo, MI, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES
PI US 2003064098 A1 20030403
AI US 2001-874504 A1 20010605 (9)
RLI Continuation-in-part of Ser. No. US 2000-731350, filed on 6 Dec 2000,
PENDING

PRAI US 1999-169856P 19991209 (60)
DT Utility
FS APPLICATION
LN.CNT 2296
INCL INCLM: 424/465.000
INCLS: 514/263.340
NCL NCLM: 424/465.000
NCLS: 514/263.340
IC [7]
ICM A61K031-522
ICS A61K009-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 22 OF 41 USPATFULL on STN

Full Text

AN 2002:258478 USPATFULL
TI Cyclooxygenase-2 inhibitor compositions having rapid onset of
therapeutic effect
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
Hageman, Michael J., Portage, MI, UNITED STATES
Haskell, Royal J., Kalamazoo, MI, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES
PI US 2002142045 A1 20021003
AI US 2002-113157 A1 20020401 (10)
RLI Continuation of Ser. No. US 2001-874504, filed on 5 Jun 2001, PENDING
Continuation-in-part of Ser. No. US 31898, PENDING A 371 of
International Ser. No. WO 2000-US32434, filed on 6 Dec 2000, UNKNOWN
PRAI US 1999-169856P 19991209 (60)
DT Utility
FS APPLICATION
LN.CNT 2294
INCL INCLM: 424/489.000
INCLS: 514/263.310; 514/263.320
NCL NCLM: 424/489.000
NCLS: 514/263.310; 514/263.320
IC [7]
ICM A61K031-522
ICS A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 23 OF 41 USPATFULL on STN

Full Text

AN 2002:90568 USPATFULL
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, UNITED STATES
Pace, Gary W., Winchester, MA, UNITED STATES
Snow, Robert A., West Chester, PA, UNITED STATES
Millar, Fay, Ladson, SC, UNITED STATES
PI US 2002047058 A1 20020425
US 6634576 B2 20031021
AI US 2001-940864 A1 20010829 (9)
PRAI US 2000-229042P 20000831 (60)
DT Utility
FS APPLICATION
LN.CNT 4197
INCL INCLM: 241/026.000
INCLS: 424/489.000
NCL NCLM: 241/021.000; 241/026.000
NCLS: 241/184.000; 424/489.000
IC [7]
ICM B02C017-00
ICS A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 24 OF 41 USPATFULL on STN

Full Text

AN 2002:61428 USPATFULL
TI Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES

Bandyopadhyay, Rebanta, Portage, MI, UNITED STATES
Singh, Satish K., Portage, MI, UNITED STATES
Hawley, Leslie C., Kalamazoo, MI, UNITED STATES
PI US 2002035264 A1 20020321
AI US 2001-904098 A1 20010712 (9)
PRAI US 2000-218101P 20000713 (60)
US 2001-279285P 20010328 (60)
US 2001-294838P 20010531 (60)
US 2001-296388P 20010606 (60)
DT Utility
FS APPLICATION
LN.CNT 1825
INCL INCLM: 546/300.000
INCLS: 546/301.000; 564/081.000; 548/377.100; 514/406.000; 514/351.000;
514/603.000
NCL NCLM: 546/300.000
NCLS: 546/301.000; 548/377.100; 564/081.000
IC [7]
ICM A61K031-435
ICS A61K031-44; A61K031-415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 25 OF 41 USPATFULL on STN

Full Text

AN 2001:116531 USPATFULL
TI Nebulized aerosols containing nanoparticle dispersions
IN Wood, Ray W., Ft. Washington, PA, United States
DeCastro, Ian, West Chester, PA, United States
Bosch, H. William, Bryn Mawr, PA, United States
PA Elan Pharma International Ltd., Shannon, Ireland (non-U.S. corporation)
PI US 6264922 B1 20010724
AI US 1997-948216 19971009 (8)
RLI Continuation of Ser. No. US 1996-589681, filed on 19 Jan 1996, now
abandoned Continuation-in-part of Ser. No. US 1995-394103, filed on 24
Feb 1995, now abandoned
DT Utility
FS GRANTED
LN.CNT 1115
INCL INCLM: 424/045.000
INCLS: 424/009.400; 424/400.000; 424/489.000
NCL NCLM: 424/045.000
NCLS: 424/009.400; 424/400.000; 424/489.000
IC [7]
ICM A61L009-04
ICS A61K049-04; A61K009-00; A61K009-14
EXF 424/45; 424/46; 424/489; 424/450; 514/826
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 26 OF 41 USPATFULL on STN

Full Text

AN 2000:149765 USPATFULL
TI Bixin colorant compositions
IN Jon, Shiu-Chung, Westmont, IL, United States
Ramagopal, Rama, Bolingbrook, IL, United States
Nicholson, Myron Donald, Lamont, IL, United States
PA Viskase Corporation, Chicago, IL, United States (U.S. corporation)
PI US 6143344 20001107
AI US 1999-255006 19990222 (9)
RLI Division of Ser. No. US 1993-124063, filed on 21 Sep 1993, now patented,
Pat. No. US 5955126
DT Utility
FS Granted
LN.CNT 1973
INCL INCLM: 426/540.000
NCL NCLM: 426/540.000
IC [7]
ICM A23L001-27
EXF 426/250; 426/540

L34 ANSWER 27 OF 41 USPATFULL on STN

Full Text

AN 1999:113414 USPATFULL

TI Self-coloring food casing
 IN Jon, Shiu-Chung, Westmont, IL, United States
 Ramagopal, Rama, Bolingbrook, IL, United States
 Nicholson, Myron Donald, Lamont, IL, United States
 PA Viskase Corporation, Chicago, IL, United States (U.S. corporation)
 PI US 5955126 19990921
 AI US 1993-124063 19930921 (8)
 DT Utility
 FS Granted
 LN.CNT 1968
 INCL INCLM: 426/105.000
 INCLS: 426/135.000
 NCL NCLM: 426/105.000
 NCLS: 426/135.000
 IC [6]
 ICM A22C013-00
 EXF 426/93; 426/105; 426/135; 426/250; 426/540; 138/118.1; 428/34.8

L34 ANSWER 28 OF 41 USPATFULL on STN

Full Text

AN 1998:138477 USPATFULL
 TI Reduction of intravenously administered nanoparticulate-formulation-
 induced adverse physiological reactions
 IN de Garavilla, Lawrence, Downingtown, PA, United States
 Liversidge, Elaine M., West Chester, PA, United States
 Liversidge, Gary G., West Chester, PA, United States
 PA Nanosystems L.L.C., King of Prussia, PA, United States (U.S.
 corporation)
 PI US 5834025 19981110
 AI US 1996-696754 19960814 (8)
 PRAI US 1995-4488P 19950929 (60)
 DT Utility
 FS Granted
 LN.CNT 994
 INCL INCLM: 424/501.000
 INCLS: 424/502.000; 428/402.210; 264/004.300
 NCL NCLM: 424/501.000
 NCLS: 264/004.300; 424/502.000; 428/402.210
 IC [6]
 ICM A61K009-50
 ICS B32B005-16; B01J013-02
 EXF 424/501; 424/502; 428/402.21; 264/4.3
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 29 OF 41 USPATFULL on STN

Full Text

AN 1998:47931 USPATFULL
 TI Aerosols containing beclomethazone nanoparticle dispersions
 IN Wiedmann, Timothy S., Minneapolis, MN, United States
 Wood, Ray W., Ft. Washington, PA, United States
 DeCastro, Ian, West Chester, PA, United States
 PA NanoSystems, L.L.C., King of Prussia, PA, United States (U.S.
 corporation)
 PI US 5747001 19980505
 AI US 1995-393973 19950224 (8)
 DT Utility
 FS Granted
 LN.CNT 895
 INCL INCLM: 424/045.000
 INCLS: 424/046.000; 424/489.000
 NCL NCLM: 424/045.000
 NCLS: 424/046.000; 424/489.000
 IC [6]
 ICM A61K009-12
 EXF 424/45; 424/46; 424/489; 514/826
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 30 OF 41 USPATFULL on STN

Full Text

AN 1998:17093 USPATFULL
 TI Nanoparticles containing the R(-)enantiomer of ibuprofen
 IN Ruddy, Stephen B., Schwenksville, PA, United States

PA Roberts, Mary E., Downingtown, PA, United States
 NanoSystems L.L.C., Collegeville, PA, United States (U.S. corporation)
 PI US 5718919 19980217
 AI US 1995-393648 19950224 (8)
 DT Utility
 FS Granted
 LN.CNT 693
 INCL INCLM: 424/489.000
 INCLS: 424/470.000; 424/490.000; 424/488.000
 NCL NCLM: 424/489.000
 NCLS: 424/470.000; 424/488.000; 424/490.000; 977/775.000; 977/915.000
 IC [6]
 ICM A61K009-16
 EXF 424/489; 424/490; 424/472; 424/488; 562/496; 514/570; 548/339
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 31 OF 41 USPATFULL on STN

Full Text

AN 96:118361 USPATFULL
 TI Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
 IN Wong, Sui-Ming, Collegeville, PA, United States
 PA NanoSystems L.L.C., Collegeville, PA, United States (U.S. corporation)
 PI US 5587143 19961224
 AI US 1994-267082 19940628 (8)
 DT Utility
 FS Granted
 LN.CNT 525
 INCL INCLM: 424/009.100
 INCLS: 424/497.000; 424/009.455; 424/009.450
 NCL NCLM: 424/009.100
 NCLS: 424/009.450; 424/009.455; 977/746.000; 977/773.000; 977/795.000; 977/847.000; 977/890.000; 977/897.000; 977/915.000; 977/926.000; 977/927.000; 977/928.000
 IC [6]
 ICM A61K049-00
 ICS A61K049-04
 EXF 424/78.31; 424/490; 424/497; 424/4.9; 514/772.3
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 32 OF 41 USPATFULL on STN

Full Text

AN 96:99005 USPATFULL
 TI Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
 IN Wong, Sui-Ming, Collegeville, PA, United States
 Newington, Ian M., Hazlemere, England
 Liversidge, Elaine M., West Chester, PA, United States
 McIntire, Gregory L., West Chester, PA, United States
 Pitt, Alan R., Sandridge, United Kingdom
 Shaw, Jack M., Aberdeen, MD, United States
 PA Nano Systems L.L.C., Collegeville, PA, United States (U.S. corporation)
 PI US 5569448 19961029
 AI US 1995-378022 19950124 (8)
 DT Utility
 FS Granted
 LN.CNT 592
 INCL INCLM: 424/009.450
 INCLS: 424/489.000; 424/490.000; 424/213.360
 NCL NCLM: 424/009.450
 NCLS: 424/489.000; 424/490.000; 427/213.360; 977/715.000; 977/773.000; 977/847.000; 977/927.000
 IC [6]
 ICM A61K009-14
 EXF 424/489; 424/490; 424/9.45; 427/213.36
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 33 OF 41 USPATFULL on STN

Full Text

AN 96:94322 USPATFULL
 TI Polyalkylene block copolymers as surface modifiers for nanoparticles
 IN Wong, Sui-Ming, Collegeville, PA, United States

Cooper, Eugene R., Berwyn, PA, United States
 Xu, Shugian, Exton, PA, United States
 PA NanoSystems L.L.C., Collegeville, PA, United States (U.S. corporation)
 PI US 5565188 19961015
 AI US 1995-393972 19950224 (8)
 DT Utility
 FS Granted
 LN.CNT 952
 INCL INCLM: 424/009.411
 INCLS: 424/009.400; 424/009.450; 424/489.000; 424/495.000; 424/499.000;
 514/718.000; 514/975.000
 NCL NCLM: 424/009.411
 NCLS: 424/009.400; 424/009.450; 424/489.000; 424/495.000; 424/499.000;
 514/718.000; 514/975.000; 977/745.000; 977/773.000; 977/775.000;
 977/788.000; 977/927.000
 IC [6]
 ICM A61K009-14
 EXF 424/489; 424/495; 424/499; 424/4; 424/5; 514/718; 514/975
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 34 OF 41 USPATFULL on STN

Full Text

AN 95:105578 USPATFULL
 TI Method of preparing nanoparticle compositions containing charged
phospholipids to reduce aggregation
 IN Na, George C., Fort Washington, PA, United States
 Rajagopalan, Natarajan, Phoenixville, PA, United States
 PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)
 PI US 5470583 19951128
 AI US 1994-240309 19940510 (8)
 RLI Division of Ser. No. US 1992-989281, filed on 11 Dec 1992, now patented,
 Pat. No. US 5336507
 DT Utility
 FS Granted
 LN.CNT 473
 INCL INCLM: 424/489.000
 INCLS: 424/484.000; 424/493.000; 424/497.000
 NCL NCLM: 424/489.000
 NCLS: 424/484.000; 424/493.000; 424/497.000; 977/746.000; 977/773.000;
 977/788.000; 977/847.000
 IC [6]
 ICM A61K009-14
 EXF 424/450; 424/4; 424/484; 424/489; 424/490-502; 436/829; 514/557;
 514/568; 264/5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 35 OF 41 USPATFULL on STN

Full Text

AN 95:80083 USPATFULL
 TI Method of making nanoparticulate X-ray blood pool contrast agents using
 high molecular weight nonionic surfactants
 IN Na, George C., Fort Washington, PA, United States
 Rajagopalan, Natarajan, Phoenixville, PA, United States
 PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)
 PI US 5447710 19950905
 AI US 1994-242492 19940513 (8)
 RLI Division of Ser. No. US 1992-991909, filed on 17 Dec 1992, now patented,
 Pat. No. US 5326552
 DT Utility
 FS Granted
 LN.CNT 545
 INCL INCLM: 424/009.455
 INCLS: 424/489.000; 424/499.000; 424/009.400; 514/005.000; 514/718.000;
 514/975.000
 NCL NCLM: 424/009.455
 NCLS: 424/009.400; 424/489.000; 424/499.000; 514/005.000; 514/718.000;
 514/975.000
 IC [6]
 ICM A61K049-04
 ICS A61K009-14
 EXF 424/5; 424/4; 424/489; 424/499; 514/5; 514/718; 514/975
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 36 OF 41 USPATFULL on STN

Full Text

AN 95:60162 USPATFULL
TI Use of tyloxapole as a nanoparticle stabilizer and dispersant
IN June, Siegfried K., Madison, CT, United States
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)
PI US 5429824 19950704
AI US 1992-990874 19921215 (7)
DT Utility
FS Granted
LN.CNT 625
INCL INCLM: 424/489.000
INCLS: 424/009.100; 424/490.000; 424/497.000; 514/951.000; 514/975.000
NCL NCLM: 424/489.000
NCLS: 424/009.100; 424/490.000; 424/497.000; 514/951.000; 514/975.000
IC [6]
ICM A61K009-14
ICS A61K009-51
EXF 424/489; 424/490; 424/497; 424/491; 424/492; 424/494; 424/496; 424/498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 37 OF 41 USPATFULL on STN

Full Text

AN 94:86191 USPATFULL
TI Use of purified surface modifiers to prevent particle aggregation during sterilization
IN Hollister, Kenneth R., Chester Springs, PA, United States
Ladd, David, Wayne, PA, United States
McIntire, Gregory L., West Chester, PA, United States
Na, George C., Fort Washington, PA, United States
Rajagopalan, Natarajan, Phoenixville, PA, United States
Yuan, Barbara O., Villanova, PA, United States
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5352459 19941004
AI US 1992-991639 19921216 (7)
DT Utility
FS Granted
LN.CNT 442
INCL INCLM: 424/489.000
INCLS: 514/951.000; 424/004.000
NCL NCLM: 424/489.000
NCLS: 424/009.450; 514/951.000
IC [5]
ICM A61K009-14
ICS A61K047-34
EXF 424/489; 424/497; 424/501; 424/4; 428/402; 428/402.24; 428/403; 428/407;
430/107; 430/111; 430/138; 502/8; 502/9; 502/402; 422/26; 514/951;
252/357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 38 OF 41 USPATFULL on STN

Full Text

AN 94:68599 USPATFULL
TI Use of charged phospholipids to reduce nanoparticle aggregation
IN Na, George C., Fort Washington, PA, United States
Rajagopalan, Natarajan, Phoenixville, PA, United States
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5336507 19940809
AI US 1992-989281 19921211 (7)
DT Utility
FS Granted
LN.CNT 462
INCL INCLM: 424/489.000
INCLS: 424/004.000; 424/484.000; 424/493.000; 424/497.000; 514/568.000
NCL NCLM: 424/489.000
NCLS: 424/009.400; 424/009.450; 424/484.000; 424/493.000; 424/497.000;
514/568.000; 977/746.000; 977/773.000; 977/788.000; 977/847.000
IC [5]
ICM A61K009-14
EXF 424/450; 424/4; 424/484; 424/489; 424/490; 424/491; 424/492-502;
436/829; 514/557; 514/568

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 39 OF 41 USPATFULL on STN

Full Text

AN 94:57597 USPATFULL
TI Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
IN Na, George C., Fort Washington, PA, United States
Rajagopalan, Natarajan, Phoenixville, PA, United States
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5326552 19940705
AI US 1992-991909 19921217 (7)
DT Utility
FS Granted
LN.CNT 489
INCL INCLM: 424/004.000
INCLS: 424/005.000; 424/489.000; 424/499.000; 514/005.000; 514/718.000; 514/975.000
NCL NCLM: 424/009.455
NCLS: 424/489.000; 424/499.000; 514/005.000; 514/718.000; 514/975.000
IC [5]
ICM A61K049-04
ICS A61K009-14; A61K009-50
EXF 424/5; 424/4; 424/9; 424/489; 424/499; 514/5; 514/718; 514/975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 40 OF 41 USPAT2 on STN

Full Text

AN 2004:334304 USPAT2
TI Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
Hageman, Michael J., Portage, MI, UNITED STATES
Haskell, Royal J., Kalamazoo, MI, UNITED STATES4)
PA Pharmacia Corporation, St. Louis, MO, UNITED STATES (U.S. corporation)
PI US 7172769 B2 20070206
WO 2001041760 20010614
AI US 2000-31898 20001206 (10)
WO 2000-US32434 20001206
20020730 PCT 371 date
PRAI US 1999-169856P 19991209 (60)
DT Utility
FS GRANTED
LN.CNT 1893
INCL INCLM: 424/501.000
INCLS: 424/489.000
NCL NCLM: 424/501.000; 424/469.000
NCLS: 424/489.000; 424/452.000; 514/406.000
EXF 424/489; 424/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 41 OF 41 USPAT2 on STN

Full Text

AN 2002:90568 USPAT2
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, United States
Pace, Gary W., Winchester, MA, United States
Snow, Robert A., West Chester, PA, United States
Millar, Fay, Ladson, SC, United States
PA RTP Pharma Inc., Durham, NC, United States (U.S. corporation)
PI US 6634576 B2 20031021
AI US 2001-940864 20010829 (9)
PRAI US 2000-229042P 20000831 (60)
DT Utility
FS GRANTED
LN.CNT 4045
INCL INCLM: 241/021.000
INCLS: 241/184.000
NCL NCLM: 241/021.000; 241/026.000
NCLS: 241/184.000; 424/489.000

IC [7]
 ICM B02C012-14
 EXF 241/21; 241/184; 241/171; 241/172; 241/23; 241/24.12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic 34

1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
 The answer numbers requested are not in the answer set.
 ENTER ANSWER NUMBER OR RANGE (1):end

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007

L1 18 S (DRUG-LIPID COMPLEX?)
 L2 18 S (DRUG-LIPID COMPLEX?)/AB,BI

FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007

L3 42 S (DRUG-LIPID COMPLEX?)
 L4 3 S (DRUG-LIPID COMPLEX?)/CLM
 L5 37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
 L6 1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
 L7 2 S L3 AND L5
 L8 1 S L4 AND L6
 L9 20 S PHOSPHOLIPID?
 L10 20 S PHOSPHOLIPID?
 L11 50032 S PHOSPHOLIPID?
 L12 5315 S PHOSPHOLIPID?/CLM
 L13 478 S L5 AND L11
 L14 9 S L6 AND L12
 L15 41 S L3 AND L11
 L16 2 S L5 AND L15
 L17 975060 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
 L18 436672 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
 L19 45055 S L11 AND L17
 L20 228 S L6 AND L18
 L21 430 S L5 AND L19
 L22 228 S L6 AND L20
 L23 2412 S L12 AND L18
 L24 7 S L6 AND L23
 L25 7 S PHARMACEUTICAL AGENT
 L26 12656 S PHARMACEUTICAL AGENT
 L27 1762 S PHARMACEUTICAL AGENT/CLM
 L28 2845 S L11 AND L26
 L29 64 S L12 AND L27
 L30 51 S L5 AND L28
 L31 4 S L6 AND L29
 L32 353 S DISPERSION MILL
 L33 15 S DISPERSION MILL/CLM
 L34 41 S L11 AND L32
 L35 1 S L12 AND L33

=> d l34 kwic 34

L34 ANSWER 34 OF 41 USPATFULL on STN

TI Method of preparing nanoparticle compositions containing charged
phospholipids to reduce aggregation
 AB . . . composition comprised of nanoparticles having a non-ionic
 surfactant as a surface modifier adsorbed on the surface thereof and a
 charged **phospholipid** as a cloud point modifier associated therewith,
 which cloud point modifier is present in an amount sufficient to
 increase the . . . cloud point of the surface modifier. A preferred
 non-ionic surfactant surface modifier is a poloxamine or tyloxapol, and
 preferred charged **phospholipid** cloud point modifiers include
 dimyristoyl phosphatidyl glycerol. This invention further discloses a
 method of making nanoparticles having a non-ionic surfactant as a
 surface modifier adsorbed on the surface and a charged **phospholipid** as
 a cloud point modifier associated therewith, comprised of contacting
 said nanoparticles with the cloud point modifier for a time. . . .
 DETD composition comprised of nanoparticles having a non-ionic

surfactant as a surface modifier adsorbed on the surface thereof and a charged **phospholipid** as a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the.

- DETD method of making nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a charged **phospholipid** as a cloud point modifier associated therewith, said method comprising contacting said nanoparticles with the cloud point modifier for a
- DETD a composition comprised of nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a **phospholipid** as a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the.
- DETD Wet grinding can take place in any suitable **dispersion mill**, including, for example, a ball mill, an attritor mill, a vibratory mill, and media mills such as a sand mill. . . .
- DETD Sterilization takes place in the presence of cloud point modifiers such as charged **phospholipids**.
- DETD Examples of cloud point modifiers include charged **phospholipids**. Charged **phospholipids** include any lipid having a net charge, i.e., any ionic **phospholipid** with a net positive or negative charge. Examples include such **phospholipids** as the synthetic **phospholipid** dimyristoyl phosphatidyl glycerol (DMPG), 1-palmitoyl-2-oleoyl phosphatidyl-serine, DL-alpha-phosphatidyl-L-serine-dipalmitoyl, and cardiolipin (diphosphatidyl glycerol). Synthetic **phospholipids** are typically available in high purity and are relatively stable and physiologically tolerable. A preferred **phospholipid** is a negatively charged **phospholipid**. A preferred negatively charged **phospholipid** is dimyristoyl phosphatidyl glycerol.
- DETD The charged **phospholipid** can be present in an amount of 0.005-20%, preferably 0.01-15%, more preferably 0.05-10%, by weight based on the total weight. . . .
- DETD The purpose of this additional non-ionic surfactant is to help mask the charges on the surface of the nanoparticles containing **phospholipids** according to the present invention. Masking these charges imparts longer circulation time for the nanoparticles used in intravenous applications.
- DETD invention further discloses a method of making nanoparticles having a non-ionic surface modifier adsorbed on the surface and a charged **phospholipid** cloud point modifier associated therewith, comprised of contacting said nanoparticles with the cloud point modifier for a time and under. . . .
- DETD Effect of **phospholipids** on the particle size of WIN 8883/Tyloxapol nanoparticles.
- DETD Samples were prepared according to the following general protocol. 0.001 grams (g) each of the tested **phospholipids** was weighed into individual 2 ml vial. Then, 0.5 ml of WIN 8883/Tyloxapol nanoparticle suspension comprised of the diagnostic agent. . . .
- DETD The following **phospholipids** were tested:
- DETD TABLE 1

Effect of **Phospholipids** on the Nanoparticulate Suspension Upon Autoclaving

Additive	Mean Particle Size	Zeta Potential
	(nm)	(mV)

Samples in the following study contained 15% WIN-8883 and. . . .

- DETD Effect of **phospholipids** on the particle size of WIN 8883 nanoparticles with other surface modifiers.
- DETD The procedure described in Example 1 was used to examine the effects of the **phospholipid** DMPG on nanoparticles prepared with surfactants such as T908, DM970 (Rhône-Poulenc), RE960 (Rhône-Poulenc) and CO990 (Rhône-Poulenc). DM970 and CO990 are. . . .
- DETD Effect of various **phospholipids** on particle size distribution.
- DETD The procedure described in Example 1 was used to examine the effects of various **phospholipids** on nanoparticles. The results of these experiments are shown in Tables 4 and 5.

DETD TABLE 5

Autoclave	Mean Size
-----------	-----------

Phospholipid

(121° C./20 min)
(nm) Polydispersity

None no 159 0.143

0.5% POPS yes 174 0.157

0.2% POPS yes 164 0.137

0.5% DPPS yes 266 0.137

0.2%.

DETD Effects of various **phospholipids** on the cloud point of tyloxapol,

DETD Most **phospholipids** with negative charge raise the cloud point of tyloxapol and stabilize the particle size after 121° C. for 20 minutes..

DETD TABLE 6

Phospholipid Cloud Point (°C.)

none 96

0.1% POPS >130

0.5% POPS >130

0.1% DPPS 117

0.1% DPPE 96

0.5% Cardiolipin 120

0.1% Cardiolipin >130

CLM What is claimed is:

... said therapeutic or diagnostic agent, said nanoparticles having from 0.005 to 20% by weight of said composition of a charged **phospholipid** as a cloud point modifier on the surface of said nanoparticles, said method comprised of contacting said nanoparticles having said. . .
9. The method of claim 1 wherein said **phospholipid** is diacyphosphatidyl glycerol.

10. The method of claim 1 wherein said **phospholipid** is dimyristoyl phosphatidyl glycerol.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

157.03

196.21

STN INTERNATIONAL LOGOFF AT 21:23:21 ON 11 JUL 2007